<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mycophenolate mofetil (Cellcept) and mycophenolate sodium (Myfortic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mycophenolate mofetil (Cellcept) and mycophenolate sodium (Myfortic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mycophenolate mofetil (Cellcept) and mycophenolate sodium (Myfortic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10882" href="/d/html/10882.html" rel="external">see "Mycophenolate mofetil (Cellcept) and mycophenolate sodium (Myfortic): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12624" href="/d/html/12624.html" rel="external">see "Mycophenolate mofetil (Cellcept) and mycophenolate sodium (Myfortic): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709159"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Only health care providers experienced in immunosuppressive therapy and management of organ transplant patients should prescribe mycophenolate. Manage patients receiving the drug in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serious infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immunosuppression may lead to increased susceptibility to bacterial, viral, fungal, and protozoal infections, including opportunistic infections and viral reactivation of hepatitis B and C, which may lead to hospitalizations and fatal outcomes.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Malignancies:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immunosuppression may lead to increased risk of development of lymphoma and other malignancies, particularly of the skin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Embryo-fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Women of reproductive potential must be counseled regarding pregnancy prevention and planning.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F198686"><span class="drugH1">Brand Names: US</span>
<ul>
<li>CellCept;</li>
<li>CellCept Intravenous;</li>
<li>Myfortic</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867607"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Mycophenolate;</li>
<li>APO-Mycophenolate;</li>
<li>APO-Mycophenolic Acid;</li>
<li>CellCept;</li>
<li>CellCept IV;</li>
<li>JAMP-Mycophenolate;</li>
<li>MAR-Mycophenolate Mofetil;</li>
<li>MAR-Mycophenolic Acid;</li>
<li>Myfortic;</li>
<li>SANDOZ Mycophenolate Mofetil;</li>
<li>TEVA-Mycophenolate</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F198710"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Immunosuppressant Agent</li></ul></div>
<div class="block doa drugH1Div" id="F198690"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Mycophenolate mofetil (CellCept) and enteric-coated (delayed-release) mycophenolate sodium (Myfortic) are not equivalent. Conversion to equimolar doses is necessary. Mycophenolate mofetil 500 mg is considered equivalent to mycophenolate sodium 360 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565799','lexi-content-ref-17302587','lexi-content-ref-17164710','lexi-content-ref-14974944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565799','lexi-content-ref-17302587','lexi-content-ref-17164710','lexi-content-ref-14974944'])">Ref</a></span>). IV and oral doses of mycophenolate mofetil are equivalent; transition to oral therapy as soon as tolerated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral, IV:</b> 500 mg to 1.5 g twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate sodium, delayed release:</i>
<b>Oral:</b> 360 to 1,080 mg twice daily.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e552d4de-28e9-4c8f-9606-7d611b4e17c6">Bullous pemphigoid, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bullous pemphigoid, adjunctive therapy (alternative agent) (off-label use): </b>
<i>Mycophenolate mofetil:</i>
<b> Oral: </b>750 mg to 1 g twice daily (maximum dose: 3 g/day) in combination with a glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18087004','lexi-content-ref-35766904','lexi-content-ref-Murrell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18087004','lexi-content-ref-35766904','lexi-content-ref-Murrell.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11273d54-f7ad-4b30-9669-1c98bba84d14">Dermatomyositis, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatomyositis (cutaneous), refractory (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Some experts recommend overlapping with preceding therapy to minimize risk for disease flares (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16415388','lexi-content-ref-Vleugels.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16415388','lexi-content-ref-Vleugels.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> Initial: 500 mg twice daily for 2 weeks then 1 g twice daily. Increase dose to 1.5 g twice daily if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16415388','lexi-content-ref-15572389','lexi-content-ref-Vleugels.1','lexi-content-ref-29114741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16415388','lexi-content-ref-15572389','lexi-content-ref-Vleugels.1','lexi-content-ref-29114741'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18e6e26c-d8fa-42b9-8a6b-e440bcbad715">Eosinophilic granulomatosis with polyangiitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an alternative induction therapy (in combination with glucocorticoids) in patients with nonsevere disease or as maintenance therapy; efficacy data are limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894','lexi-content-ref-15030353','lexi-content-ref-34350491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894','lexi-content-ref-15030353','lexi-content-ref-34350491'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> 750 mg to 1.5 g twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894','lexi-content-ref-15030353','lexi-content-ref-King.1','lexi-content-ref-34350491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894','lexi-content-ref-15030353','lexi-content-ref-King.1','lexi-content-ref-34350491'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ce8b60c-27b7-4072-ba33-a2d17b458bcb">Focal segmental glomerulosclerosis, glucocorticoid-dependent or glucocorticoid-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal segmental glomerulosclerosis, glucocorticoid-dependent or glucocorticoid-resistant (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Some experts reserve use for patients who have either not responded to or should not be exposed to calcineurin inhibitors, or who have had a partial response to calcineurin inhibitors but developed signs of toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> 750 mg to 1 g twice daily in combination with low-dose glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1','lexi-content-ref-21734640','lexi-content-ref-17989103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1','lexi-content-ref-21734640','lexi-content-ref-17989103'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate sodium, delayed release:</i>
<b>Oral:</b> 540 to 720 mg twice daily in combination with low-dose glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dfba4e53-686f-4c05-bcd0-9183006af157">Graft-versus-host disease in allogeneic hematopoietic cell transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease in allogeneic hematopoietic cell transplantation (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Prophylaxis:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Generally reserved for patients receiving nonmyeloablative or reduced intensity conditioning regimens; may be an alternative antimetabolite for patients receiving myeloablative conditioning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32004485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32004485'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate mofetil:</i>
<b> Oral, IV:</b> 15 mg/kg twice daily beginning on day 0 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16344316','lexi-content-ref-12393457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16344316','lexi-content-ref-12393457'])">Ref</a></span>) <b>or</b> 10 to 15 mg/kg 3 times daily beginning on day 0 or day +1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32004485','lexi-content-ref-16545729','lexi-content-ref-18727660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32004485','lexi-content-ref-16545729','lexi-content-ref-18727660'])">Ref</a></span>); usual dose: 1 g 2 to 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Zeiser.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Zeiser.1'])">Ref</a></span>). Administer in combination with a calcineurin inhibitor and adjust dose based on toxicities. The duration is typically ~1 month for matched-related donation and 2 to 3 months for matched-unrelated donation; individualize duration based on risk of relapse and risk of graft-vs-host disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32004485']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32004485'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment, acute or chronic disease, glucocorticoid-resistant (alternative agent):</i></b>
<i>Mycophenolate mofetil: </i>
<b>Oral, IV:</b> 1 to 1.5 g twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19377515','lexi-content-ref-10482936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19377515','lexi-content-ref-10482936'])">Ref</a></span>) <b>or</b> 1 g every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25170121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25170121'])">Ref</a></span>) as part of a combination regimen.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3d42c0e-35da-49e3-ac8b-92cee4dcf708">Granulomatosis with polyangiitis and microscopic polyangiitis, maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Granulomatosis with polyangiitis and microscopic polyangiitis, maintenance therapy (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Efficacy data are limited, with mixed results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21060104','lexi-content-ref-16286784','lexi-content-ref-15077273']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21060104','lexi-content-ref-16286784','lexi-content-ref-15077273'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> 750 mg to 1.5 g twice daily. Continue for a duration of 12 to 24 months after stable remission is induced (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21060104','lexi-content-ref-16286784','lexi-content-ref-15077273','lexi-content-ref-Merkel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21060104','lexi-content-ref-16286784','lexi-content-ref-15077273','lexi-content-ref-Merkel.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80fa41b7-b3df-4c49-a5c4-c9d71f655c44">Hepatitis, autoimmune, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatitis, autoimmune, refractory (alternative agent) (off-label use): </b>
<i>Mycophenolate mofetil</i>: <b>Oral:</b> 1 g twice daily in combination with a glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31863477','lexi-content-ref-17509945','lexi-content-ref-29050991','lexi-content-ref-26991238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31863477','lexi-content-ref-17509945','lexi-content-ref-29050991','lexi-content-ref-26991238'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0e8695a-ab23-4579-8a2a-e35dd8656c8d">IgA nephropathy, primary, nonvariant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>IgA nephropathy, primary, nonvariant (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May consider for use as an alternative to glucocorticoids or as a glucocorticoid-sparing agent in selected patients at high risk of chronic kidney disease progression (eg, proteinuria ≥ 0.75 to 1 g/day) despite 3 to 6 months of optimized doses of nonimmunosuppressive therapies (eg, renin-angiotensin system inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.2','lexi-content-ref-34556256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.2','lexi-content-ref-34556256'])">Ref</a></span>). The optimal dose has not been established and may vary based on institutional protocols and patient-specific factors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> 750 mg to 1 g twice daily for 6 to 12 months; may be followed by a lower maintenance dose for an additional 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36745456','lexi-content-ref-16014059','lexi-content-ref-20032964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36745456','lexi-content-ref-16014059','lexi-content-ref-20032964'])">Ref</a></span>). Some experts initiate at a lower dose (eg, 500 mg twice daily) and increase as tolerated over several weeks to the recommended maintenance dose, then slowly taper and discontinue after 12 months of therapy. If disease worsens after 4 to 6 months of treatment, consider switching to an alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb5bee0a-86ca-4c07-82ba-6ef1de8d3025">Interstitial nephritis, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial nephritis, acute (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve for use in glucocorticoid-resistant or glucocorticoid-dependent disease; based on limited data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33564419','lexi-content-ref-17699278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33564419','lexi-content-ref-17699278'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> Initial: 500 mg twice daily; titrate up to goal dose of 1 g twice daily as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33564419','lexi-content-ref-Falk.1','lexi-content-ref-17699278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33564419','lexi-content-ref-Falk.1','lexi-content-ref-17699278'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8aa35b4c-96d5-4920-906c-7235766867a7">Interstitial pneumonia/interstitial lung disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial pneumonia/interstitial lung disease (off-label use): </b>
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> Initial: 500 mg twice daily; increase to goal maintenance dose of 750 mg to 1.5 g twice daily as tolerated; give in combination with a glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27692137','lexi-content-ref-23457378','lexi-content-ref-Flaherty.1','lexi-content-ref-Lake.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27692137','lexi-content-ref-23457378','lexi-content-ref-Flaherty.1','lexi-content-ref-Lake.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="311fe009-0f2e-4adf-a04a-27361a619f87">Lupus erythematosus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lupus erythematosus (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Discoid lupus and subacute cutaneous lupus, refractory (alternative agent): </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Dose not well established.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> 1 to 1.5 g twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33404096','lexi-content-ref-21641078','lexi-content-ref-12472362','lexi-content-ref-12100205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33404096','lexi-content-ref-21641078','lexi-content-ref-12472362','lexi-content-ref-12100205'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate sodium, delayed release:</i>
<b>Oral:</b> 720 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17408395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17408395'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration: ~2 to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Clarke.1','lexi-content-ref-21641078','lexi-content-ref-17408395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Clarke.1','lexi-content-ref-21641078','lexi-content-ref-17408395'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Lupus nephritis, focal or diffuse:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Give as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22556106','lexi-content-ref-26835147','lexi-content-ref-34560137','lexi-content-ref-21976398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22556106','lexi-content-ref-26835147','lexi-content-ref-34560137','lexi-content-ref-21976398'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Initial therapy:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mycophenolate mofetil</i>: <b>Oral:</b> 1 to 1.5 g twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22556106','lexi-content-ref-32220834','lexi-content-ref-16221103','lexi-content-ref-32220510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22556106','lexi-content-ref-32220834','lexi-content-ref-16221103','lexi-content-ref-32220510'])">Ref</a></span>) <b>or </b>500 mg twice daily for 1 week, then 1 g twice daily for 1 week, then 1.5 g twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19369404']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19369404'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mycophenolate sodium, delayed release</i>: <b>Oral:</b> 720 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26835147','lexi-content-ref-28450313','lexi-content-ref-32220510','lexi-content-ref-21976398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26835147','lexi-content-ref-28450313','lexi-content-ref-32220510','lexi-content-ref-21976398'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Duration: Variable, ~6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22556106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22556106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Subsequent therapy:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mycophenolate mofetil: </i>
<b>Oral:</b> 1 g twice daily (range: 500 mg to 3 g/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22556106','lexi-content-ref-14999109','lexi-content-ref-22087680','lexi-content-ref-32220834','lexi-content-ref-20833738','lexi-content-ref-32220510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22556106','lexi-content-ref-14999109','lexi-content-ref-22087680','lexi-content-ref-32220834','lexi-content-ref-20833738','lexi-content-ref-32220510'])">Ref</a></span>). Duration is typically ≥2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999109','lexi-content-ref-22087680','lexi-content-ref-Falk.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999109','lexi-content-ref-22087680','lexi-content-ref-Falk.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mycophenolate sodium, delayed release</i>: <b>Oral:</b> 360 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26835147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26835147'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c33ef22-65ff-4e79-9241-9bbe2290b881">Minimal change disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Minimal change disease (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve use for patients who are unable to tolerate high-dose glucocorticoid monotherapy or who have frequently relapsing disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-30385039','lexi-content-ref-28979773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-30385039','lexi-content-ref-28979773'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> 500 mg twice daily for ~1 week, then 1 g twice daily; give in combination with low-dose glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-Meyrier.1','lexi-content-ref-28979773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-Meyrier.1','lexi-content-ref-28979773'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate sodium, delayed release:</i>
<b> Oral:</b> 360 mg twice daily for ~1 week, then 720 mg twice daily; give in combination with low-dose glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-Meyrier.1','lexi-content-ref-30385039','lexi-content-ref-28979773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-Meyrier.1','lexi-content-ref-30385039','lexi-content-ref-28979773'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e5206140-8160-4d4c-94ee-5cc0a17c4655">Myasthenia gravis, chronic immunosuppressive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis, chronic immunosuppressive therapy (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use as monotherapy or in combination with glucocorticoids in patients with glucocorticoid-resistant or glucocorticoid-dependent disease. Due to delayed onset of clinical response, most often initially given in combination with a glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20405499','lexi-content-ref-14638974','lexi-content-ref-27358333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20405499','lexi-content-ref-14638974','lexi-content-ref-27358333'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> Initial: 500 mg twice daily; increase after 1 to 4 weeks based on response and tolerability to a maintenance dose of 1 to 1.5 g twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bird.1','lexi-content-ref-14638974','lexi-content-ref-27358333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bird.1','lexi-content-ref-14638974','lexi-content-ref-27358333'])">Ref</a></span>). Onset of clinical response to mycophenolate may take up to 6 to 12 months, with a maximum effect not apparent until 1 to 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20405499','lexi-content-ref-27358333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20405499','lexi-content-ref-27358333'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="750ebf57-daad-42cf-99af-5d7b7072eaa9">Pemphigus vulgaris and pemphigus foliaceus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pemphigus vulgaris and pemphigus foliaceus (alternative agent) (adjunctive agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b> Oral: </b>1 g twice daily in combination with a glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20410913','lexi-content-ref-17583373','lexi-content-ref-Hertl.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20410913','lexi-content-ref-17583373','lexi-content-ref-Hertl.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate sodium, delayed release:</i>
<b>Oral:</b> 720 mg twice daily in combination with a glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hertl.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hertl.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="accd1189-8e66-4e58-ae04-57fdff5b82c2">Solid organ transplantation, maintenance immunosuppressive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid organ transplantation, maintenance immunosuppressive therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Heart transplantation:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate mofetil: </i>
<b>Oral, IV:</b> 1 to 1.5 g twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15896747','lexi-content-ref-23415313','lexi-content-ref-16890114','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15896747','lexi-content-ref-23415313','lexi-content-ref-16890114','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate sodium, delayed release (off-label use):</i>
<b>Oral:</b> 720 to 1,080 mg twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16890114','lexi-content-ref-18555088','lexi-content-ref-Pham.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16890114','lexi-content-ref-18555088','lexi-content-ref-Pham.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Kidney transplantation: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate mofetil: </i>
<b>Oral, IV:</b> 1 g (range: 500 mg to 1 g) twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10459543','lexi-content-ref-Hardinger.1','lexi-content-ref-19845597','lexi-content-ref-8623181','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10459543','lexi-content-ref-Hardinger.1','lexi-content-ref-19845597','lexi-content-ref-8623181','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate sodium, delayed release:</i>
<b>Oral:</b> 720 mg (range: 360 to 720 mg) twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hardinger.1','lexi-content-ref-19845597','lexi-content-ref-14974944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hardinger.1','lexi-content-ref-19845597','lexi-content-ref-14974944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Liver transplantation:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate mofetil:</i>
<b>Oral, IV:</b> 1 g twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9458011','lexi-content-ref-11349266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9458011','lexi-content-ref-11349266'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate sodium, delayed release (off-label use):</i>
<b>Oral:</b> 720 mg twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25420815','lexi-content-ref-28133906']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25420815','lexi-content-ref-28133906'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Lung transplantation (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate mofetil:</i>
<b>Oral, IV:</b> 1 to 1.5 g twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20394831','lexi-content-ref-12698153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20394831','lexi-content-ref-12698153'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mycophenolate sodium, delayed release:</i>
<b>Oral:</b> 720 to 1,080 mg twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Diamond.1','lexi-content-ref-25049068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Diamond.1','lexi-content-ref-25049068'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="17423048-3542-4ae6-830d-7c07256b333d">Systemic sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic sclerosis (scleroderma) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used primarily in patients with diffuse skin disease or interstitial lung disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Denton.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Denton.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil</i>: <b>Oral:</b> Initial: 500 mg twice daily; increase up to 1.5 g twice daily as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19846575','lexi-content-ref-27469583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19846575','lexi-content-ref-27469583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate sodium, delayed release:</i>
<b>Oral:</b> Initial: 360 mg twice daily; increase up to 720 mg twice daily as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23307324','lexi-content-ref-21881859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23307324','lexi-content-ref-21881859'])">Ref</a></span>). Based on data with mycophenolate mofetil and equivalency, may consider increasing dose to 1,080 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19846575','lexi-content-ref-14565799','lexi-content-ref-27469583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19846575','lexi-content-ref-14565799','lexi-content-ref-27469583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3366b908-8b85-4957-b3ac-11825415246c">Takayasu arteritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Takayasu arteritis (alternative agent) (off-label use): </b>
<i>Mycophenolate mofetil:</i>
<b> Oral: </b>750 mg to 1.5 g twice daily as tolerated in combination with a glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31270110','lexi-content-ref-20054700','lexi-content-ref-29096935','lexi-content-ref-27924855','lexi-content-ref-34235884','lexi-content-ref-Merkel.2','lexi-content-ref-17332971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31270110','lexi-content-ref-20054700','lexi-content-ref-29096935','lexi-content-ref-27924855','lexi-content-ref-34235884','lexi-content-ref-Merkel.2','lexi-content-ref-17332971'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="453dc3ca-df1d-4d49-86a6-814a83391a4f">Toxicities associated with immune checkpoint inhibitor therapy, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxicities associated with immune checkpoint inhibitor therapy, treatment (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For treatment of immune-mediated, glucocorticoid-refractory cardiac, hematologic, hepatic, kidney, musculoskeletal, or pulmonary toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-33568350','lexi-content-ref-30395075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-33568350','lexi-content-ref-30395075'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral, IV:</b> 500 mg to 1 g twice daily in combination with glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-31656561','lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-31656561','lexi-content-ref-34172516'])">Ref</a></span>); doses of up to 1.5 g twice daily have been used for severe pneumonitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="241167ae-37ec-4f5e-83cd-2298bcb5b902">Uveitis, noninfectious</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis, noninfectious (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Some experts reserve for use in patients with severe or bilateral disease, active inflammation, or glucocorticoid-resistant or glucocorticoid-dependent disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosenbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosenbaum.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil:</i>
<b>Oral:</b> Initial: 500 mg twice daily for 2 weeks; increase to a maintenance dose of 1 to 1.5 g twice daily as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18579209','lexi-content-ref-24917273','lexi-content-ref-31503307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18579209','lexi-content-ref-24917273','lexi-content-ref-31503307'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate sodium, delayed release:</i>
<b>Oral:</b> Initial: 360 mg twice daily for 1 week; increase to a maintenance dose of 720 mg twice daily as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28903965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28903965'])">Ref</a></span>). Based on data with mycophenolate mofetil and equivalency, may consider increasing dose to 1,080 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565799','lexi-content-ref-18579209','lexi-content-ref-31503307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565799','lexi-content-ref-18579209','lexi-content-ref-31503307'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991238"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Dosing varies by indication, concomitant medications, time post-transplant, genetic factors, and kidney function; interindividual variability is significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17201457','lexi-content-ref-24792322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17201457','lexi-content-ref-24792322'])">Ref</a></span>). Mycophenolic acid (MPA) (active metabolite) exposure increases as kidney function decreases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17700162','lexi-content-ref-17201457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17700162','lexi-content-ref-17201457'])">Ref</a></span>); mycophenolic acid glucuronide (inactive metabolite) accumulates in severe kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17201457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17201457'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Immediate post-transplant period:</b> No dosage adjustment necessary for any degree of kidney dysfunction. Rapid achievement of adequate immunosuppressive concentrations is necessary to prevent rejection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> Immediate post-transplant period may vary; refer to institution-specific protocols for further details.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic use (including outside the immediate post-transplant period): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥25 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary. Therapeutic drug monitoring may be considered for patients with eGFR &lt;60 mL/minute/1.73 m<sup>2</sup> when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;25 mL/minute/1.73 m<sup>2</sup>: No initial dosage adjustment necessary; use with caution. For nontransplant indications, consider limiting dose to mycophenolate mofetil 1 g twice daily or mycophenolate sodium delayed release 720 mg twice daily, or monitor closely for adverse effects such as leukopenia from increased MPA exposure. Therapeutic drug monitoring is recommended when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33711005','lexi-content-ref-20056756','lexi-content-ref-16628123','lexi-content-ref-16452491','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33711005','lexi-content-ref-20056756','lexi-content-ref-16628123','lexi-content-ref-16452491','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9630824','lexi-content-ref-10720968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9630824','lexi-content-ref-10720968'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> No initial dosage adjustment necessary; use with caution. For nontransplant indications, consider limiting dose to mycophenolate mofetil 1 g twice daily or mycophenolate sodium delayed release 720 mg twice daily, or monitor closely for adverse effects from increased MPA exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nemecek.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nemecek.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Increased incidence of adverse effects (eg, GI symptoms, anemia, leukopenia) requiring dose reduction or discontinuation have been reported in patients with end-stage kidney disease (ESKD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12078944','lexi-content-ref-9630824','lexi-content-ref-10720968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12078944','lexi-content-ref-9630824','lexi-content-ref-10720968'])">Ref</a></span>). Therapeutic drug monitoring is recommended when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10720968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10720968'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> No initial dosage adjustment necessary; use with caution; however, for nontransplant indications, consider limiting dose to mycophenolate mofetil 1 g twice daily or mycophenolate sodium delayed release 720 mg twice daily, or monitor closely for adverse effects from increased MPA exposure. Increased incidence of adverse effects (eg, GI symptoms, anemia, leukopenia) requiring dose reduction or discontinuation have been reported in patients with ESKD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12078944','lexi-content-ref-9630824','lexi-content-ref-10720968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12078944','lexi-content-ref-9630824','lexi-content-ref-10720968'])">Ref</a></span>). Therapeutic drug monitoring is recommended when available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<b>Note:</b></b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Close monitoring of response and for adverse effects (eg, GI symptoms, anemia, leukopenia) due to drug accumulation is important. Therapeutic drug monitoring is recommended when available due to alterations in protein binding associated with critical illness, which may increase free mycophenolate concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18223470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18223470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> Dose as in eGFR &lt;25 mL/minute/1.73 m<sup>2</sup>, as removal by CRRT is expected to be insignificant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18223470','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18223470','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and for adverse effects (eg, GI symptoms, anemia, leukopenia) due to drug accumulation is important. Therapeutic drug monitoring is recommended when available due to alterations in protein binding associated with critical illness, which may increase free mycophenolate concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18223470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18223470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b> Dose as in eGFR &lt;25 mL/minute/1.73 m<sup>2</sup>, as removal by PIRRT is expected to be insignificant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988482"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment is recommended for renal patients with severe hepatic parenchymal disease; however, it is not currently known whether dosage adjustments are necessary for hepatic disease with other etiologies. Increased monitoring may be necessary in patients with hyperbilirubinemia and/or hypoalbuminemia; displacement or decreased number of binding sites may occur resulting in an increase concentration of MPA/MPAG free fraction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17201457']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17201457'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F3022884"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Neutropenia (ANC &lt;1.3 x 10<sup>3</sup>/mcL): Dosing should be interrupted or the dose reduced, appropriate diagnostic tests performed and patients managed appropriately</p></div>
<div class="block doe drugH1Div" id="F198691"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Dosage is the same as for younger patients; however, dosing should be cautious due to possibility of increased hepatic, renal, or cardiac dysfunction. Patients ≥65 years of age may be at an increased risk of certain infections, GI hemorrhage, and pulmonary edema, as compared to patients &lt;65 years of age.</p></div>
<div class="block dop drugH1Div" id="F198703"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12624" href="/d/html/12624.html" rel="external">see "Mycophenolate mofetil (Cellcept) and mycophenolate sodium (Myfortic): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> The parenteral formulation for IV administration may be used for up to 14 days; transition to oral therapy as soon as tolerated. Mycophenolate mofetil (CellCept) tablets, capsules, and suspension, and mycophenolate sodium as the delayed-release tablet formulation (Myfortic) are not equivalent on a mg:mg basis due to differences in the rate of absorption. Mycophenolate sodium delayed release 720 mg twice daily was shown to be bioequivalent to mycophenolate mofetil 1,000 mg twice daily. Consult institution-specific protocols.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab5ed33d-f861-4d21-a97f-0182da50024b">Heart transplantation, immunosuppressive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart transplantation, immunosuppressive therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil (CellCept):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b></b>Infants ≥3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Suspension: Oral: Initial: 600 mg/m<sup>2</sup>/dose twice daily; if tolerated, may increase to 900 mg/m<sup>2</sup>/dose twice daily; maximum daily dose: 3,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Tablets or capsules: For patients with a BSA ≥1.25 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b></b>BSA 1.25 to &lt;1.5 m<sup>2</sup>: Oral: Initial: 750 mg twice daily; if tolerated, may increase dose as appropriate (using twice-daily dosing); maximum daily maintenance dose: 3,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">BSA ≥1.5 m<sup>2</sup>: Oral: Initial: 1,000 mg twice daily; if tolerated, may increase dose as appropriate (using twice-daily dosing); maximum daily maintenance dose: 3,000 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c73fc976-377d-4612-a51e-36bf19b6427b">Kidney transplantation, immunosuppressive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney transplantation, immunosuppressive therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil (CellCept):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Suspension: Oral: 600 mg/m<sup>2</sup>/dose twice daily; maximum daily dose: 2,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Tablets or capsules:</p>
<p style="text-indent:-2em;margin-left:10em;">BSA 1.25 to &lt;1.5 m<sup>2</sup>: Oral: 750 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:10em;">BSA ≥1.5 m<sup>2</sup>: Oral: 1,000 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate sodium delayed-release tablets (Myfortic):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥5 years and Adolescents: Oral: 400 mg/m<sup>2</sup>/dose twice daily; maximum daily dose: 1,440 mg/<b>day</b>; avoid partial tablet doses by rounding doses to nearest whole tablet size as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">BSA &lt;1.19 m<sup>2</sup>: Use of this formulation is not recommended.</p>
<p style="text-indent:-2em;margin-left:8em;">BSA 1.19 to 1.58 m<sup>2</sup>: Oral: 540 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">BSA &gt;1.58 m<sup>2</sup>: Oral: 720 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e296018-740f-4073-96a6-af596e9a8d0a">Liver transplantation, immunosuppressive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Liver transplantation, immunosuppressive therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil (Cellcept):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b></b>Infants ≥3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Suspension: Oral: Initial: 600 mg/m<sup>2</sup>/dose twice daily; if tolerated, may increase to 900 mg/m<sup>2</sup>/dose twice daily; maximum daily dose: 3,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Tablets or capsules: For patients with a BSA ≥1.25 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:10em;">BSA 1.25 to &lt;1.5 m<sup>2</sup>: Oral: Initial: 750 mg twice daily; if tolerated, may increase dose as appropriate (twice-daily dosing); maximum daily maintenance dose: 3,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">BSA ≥1.5 m<sup>2</sup>: Oral: Initial: 1,000 mg twice daily; if tolerated, may increase dose as appropriate (twice-daily dosing); maximum daily maintenance dose: 3,000 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eab8f0bd-af63-4233-929f-24083e3b8bec">Lupus nephritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lupus nephritis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil (CellCept):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">BSA-based dosing: Induction and Maintenance: 300 to 600 mg/m<sup>2</sup>/dose twice daily; maximum daily dose: 3,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20581019','lexi-content-ref-19727839','lexi-content-ref-30348175','lexi-content-ref-17664180','lexi-content-ref-20222881','lexi-content-ref-19626343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20581019','lexi-content-ref-19727839','lexi-content-ref-30348175','lexi-content-ref-17664180','lexi-content-ref-20222881','lexi-content-ref-19626343'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d21fe61-4ec6-4b88-aa3c-5747b53daca5">Nephrotic syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrotic syndrome:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mycophenolate mofetil (CellCept):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Frequently relapsing:</i></p>
<p style="text-indent:-2em;margin-left:10em;">BSA-based dosing: 600 mg/m<sup>2</sup>/dose twice daily for at least 12 months; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23871408','lexi-content-ref-19651590','lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23871408','lexi-content-ref-19651590','lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Weight-based dosing: 12.5 to 18 mg/kg/dose twice daily; maximum daily dose: 2,000 mg/<b>day</b> for 1 to 2 years with a tapering dose of prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19651590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19651590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Steroid-dependent (for steroid sparing effect):</i></p>
<p style="text-indent:-2em;margin-left:10em;">BSA-based dosing: 600 mg/m<sup>2</sup>/dose twice daily for at least 12 months; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19651590','lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19651590','lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Weight-based dosing: 12 to 18 mg/kg/dose twice daily; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19651590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19651590'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Hematologic: ANC &lt;1.3 x 10<sup>3</sup>/μL or anemia: Dosing should be interrupted or the dose reduced.</p></div>
<div class="block dorp drugH1Div" id="F51130394"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate mofetil (CellCept): Infants ≥3 months, Children, and Adolescents: <b>Note</b>: Dose adjustments are not needed in kidney transplant recipients experiencing delayed graft function postoperatively. There are no pediatric-specific recommendations for liver or heart transplantation.</p>
<p style="text-indent:-2em;margin-left:4em;">Kidney transplant with mild to moderate chronic impairment (GFR ≥25 mL/minute/1.73 m<sup>2</sup>): No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Kidney transplant with severe chronic impairment (GFR &lt;25 mL/minute/1.73 m<sup>2</sup>): Avoid doses &gt;1,000 mg/dose twice daily; monitor carefully.</p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate delayed-release tablet (Myfortic): Children ≥5 years and Adolescents: No dosage adjustments are provided in the manufacturer's labeling; however, based on experience with other salt forms, it is likely that no dose adjustments are needed in kidney transplant recipients experiencing delayed graft function postoperatively; monitor carefully for potential concentration dependent adverse events.</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis:</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Not removed; supplemental dose is not necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Supplemental dose is not necessary.</p></div>
<div class="block dohp drugH1Div" id="F51130395"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate mofetil (CellCept): Infants ≥3 months, Children, and Adolescents: No dosage adjustment is recommended for renal patients with severe hepatic parenchymal disease; however, it is not currently known whether dosage adjustments are necessary for hepatic disease with other etiologies.</p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate delayed release (Myfortic): Children ≥5 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F55765760"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute inflammatory syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate administration may result in a reversible <b>acute inflammatory syndrome</b> (AIS) which is characterized by fever, arthralgias, arthritis, myalgias, and increased inflammatory markers (eg, C-reactive protein, erythrocyte sedimentation rate) without evidence of infection or disease recurrence. Improvement typically occurs within 24 to 48 hours of discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism unknown; AIS is a pro-inflammatory reaction without evidence of infection or disease recurrence.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; according to the manufacturer, symptoms occur within weeks to months of initiation of treatment or dose increases.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate administration may result in reversible bone marrow suppression, most commonly <b>anemia</b> or <b>leukopenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31332670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31332670'])">Ref</a></span>). Neutropenia can be severe and may result in an increased risk of infectious complications. <b>Thrombocytopenia</b> may also commonly occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33121819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33121819'])">Ref</a></span>). In patients being treated for systemic lupus erythematosus (SLE), hematologic disorders may occur less frequently with mycophenolate as compared to other treatment options (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31293110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31293110'])">Ref</a></span>). Bone marrow suppression may warrant treatment interruption, dosage adjustment, or discontinuation; the risk of reduced immunosuppression and graft rejection should be considered in transplant recipients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism unknown; related to pharmacologic action. Mycophenolate is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) which can result in the induction of apoptosis or inhibition of cell proliferation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15110637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15110637'])">Ref</a></span>). While some evidence exists that suggest a relationship between the degree of mycophenolate exposure (eg, dose, total mycophenolate AUC, free mycophenolate AUC, metabolite(s) AUC, trough concentrations) and the manifestation of bone marrow suppression, data are inconclusive to support a consistent relationship (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18668650','lexi-content-ref-32567256','lexi-content-ref-30178220','lexi-content-ref-31332670','lexi-content-ref-26082342','lexi-content-ref-23758434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18668650','lexi-content-ref-32567256','lexi-content-ref-30178220','lexi-content-ref-31332670','lexi-content-ref-26082342','lexi-content-ref-23758434'])">Ref</a></span>). In addition, the impact of transplantation and/or other disease processes must be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23758434','lexi-content-ref-25836768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23758434','lexi-content-ref-25836768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; according to the manufacturer, neutropenia was observed most frequently in the period from 31 to 180 days post-transplant in patients treated for prevention of kidney, heart, and liver rejection. One retrospective trial found the average onset of leukopenia, anemia, and thrombocytopenia to be ~5 to 6 months in patients receiving mycophenolate after kidney transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32567256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32567256'])">Ref</a></span>). Because the degree of mycophenolate exposure may relate to the manifestation of bone marrow suppression, onset may be affected by dose adjustments or pharmacokinetic variability. Genetic factors may impact onset of leukopenia; one trial found that certain single nucleotide polymorphisms (SNPs) in the IMPDH1 gene were associated with an increased time to leukopenia by ~90 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28869324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28869324'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Increased mycophenolate exposure; <b>Note:</b> Data are inconclusive to support a consistent relationship (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31332670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31332670'])">Ref</a></span>). There is a high amount of inter- and intrapatient variability with mycophenolate pharmacokinetics due to differences in formulations; gastric pH fluctuations; genetics (eg, UGT-glucuronosyltransferases, transporters); renal and hepatic function; enterohepatic recirculation; etc (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31332670','lexi-content-ref-31062373','lexi-content-ref-26082342','lexi-content-ref-28869324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31332670','lexi-content-ref-31062373','lexi-content-ref-26082342','lexi-content-ref-28869324'])">Ref</a></span>). Increased risk of bone marrow suppression may be associated with:</p>
<p style="text-indent:-2em;margin-left:8em;">- increased trough concentrations, C<sub>max</sub>, or AUC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18668650','lexi-content-ref-32567256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18668650','lexi-content-ref-32567256'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32567256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32567256'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- decreased clearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12078944','lexi-content-ref-30178220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12078944','lexi-content-ref-30178220'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of other agents known to cause bone marrow suppression</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI effects, including <b>diarrhea</b>, <b>abdominal</b>
<b>pain</b>, <b>nausea</b>, and <b>vomiting</b>, are among the most common adverse effects associated with the use of mycophenolate. Additional symptoms may include <b>constipation</b>, <b>decreased appetite</b>,<b> dyspepsia</b>, and <b>flatulence</b>. Use may rarely be associated with <b>gastric or duodenal ulcers</b>, <b>gastrointestinal hemorrhage</b>, and/or <b>perforation</b>. Patients who undergo colonoscopy for GI complaints secondary to mycophenolate have demonstrated endoscopic features of erythema and erosions/ulcers and histological findings including acute colitis-like findings, inflammatory bowel disease-like characteristics, ischemia-like findings, and graft-versus-host disease-like features (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26126799','lexi-content-ref-25142167']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26126799','lexi-content-ref-25142167'])">Ref</a></span>). Presence of GI symptoms may result in noncompliance, slower rates of dose titration, dose reduction, treatment interruption, and/or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17275481','lexi-content-ref-11522119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17275481','lexi-content-ref-11522119'])">Ref</a></span>); the risk of reduced immunosuppression and graft rejection should be considered in transplant recipients. Clinicians should note that some GI effects may be the result of an infectious process (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33132635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33132635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism is unknown. Existing theories include direct gut toxicity of the mofetil ester or local toxicity of acyl-mycophenolic acid glucuronide in the GI tract; may also be a result of the pharmacologic action (inhibition of inosine monophosphate dehydrogenase [IMPDH] and subsequent inhibition of enterocyte proliferation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17275481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17275481'])">Ref</a></span>). While some evidence exists that suggest a relationship between the degree of mycophenolate exposure (eg, dose, total mycophenolate AUC, free mycophenolate AUC, metabolite(s) AUC, trough concentrations) and the risk of GI effects, data are inconclusive to support a consistent relationship (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18668650','lexi-content-ref-31332670','lexi-content-ref-26082342','lexi-content-ref-15518748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18668650','lexi-content-ref-31332670','lexi-content-ref-26082342','lexi-content-ref-15518748'])">Ref</a></span>). In addition, the impact of other disease processes must be considered (eg, systemic sclerosis, graft-versus-host disease, infectious processes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33132635','lexi-content-ref-25933090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33132635','lexi-content-ref-25933090'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; one retrospective study of patients receiving mycophenolate who had undergone an upper GI tract biopsy found that symptoms developed between 1 month and 10 years post-transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19542873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19542873'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of calcineurin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17275481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17275481'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of a nonenteric-coated formulation; <b>Note: </b>An enteric-coated formulation (Myfortic) was developed to delay release of mycophenolate until the small intestine with a goal of decreasing GI effects; however, data are conflicting on the impact of the enteric-coated formulation on the risk of GI side effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14974945','lexi-content-ref-20795786','lexi-content-ref-25196230','lexi-content-ref-18394000','lexi-content-ref-21760569','lexi-content-ref-14974944','lexi-content-ref-20177347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14974945','lexi-content-ref-20795786','lexi-content-ref-25196230','lexi-content-ref-18394000','lexi-content-ref-21760569','lexi-content-ref-14974944','lexi-content-ref-20177347'])">Ref</a></span>). One study showed that conversion to an enteric-coated formulation may be particularly helpful between 6- and 12-months post-transplantation or in patients with indigestion, diabetes, on concomitant corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21245794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21245794'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased mycophenolate exposure; <b>Note:</b> Data are inconclusive to support a consistent relationship (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31332670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31332670'])">Ref</a></span>). There is a high amount of inter- and intrapatient variability with mycophenolate pharmacokinetics due to differences in formulations; gastric pH fluctuations; genetics (eg, UGT-glucuronosyltransferases, transporters); renal and hepatic function; enterohepatic recirculation; etc (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31332670','lexi-content-ref-31062373','lexi-content-ref-26082342','lexi-content-ref-28869324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31332670','lexi-content-ref-31062373','lexi-content-ref-26082342','lexi-content-ref-28869324'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31062373','lexi-content-ref-31028595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31062373','lexi-content-ref-31028595'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate is an immunosuppressant; therefore, use may result in <b>bacterial</b>, <b>viral</b>, <b>fungal</b>, and<b> protozoal infections</b>, including opportunistic infections. Infections may be severe and potentially fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20217287']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20217287'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Viral infections reported with the use of mycophenolate include<b> polyomavirus infection </b>(which may result in polyomavirus associated nephropathy [PVAN]), JC virus-associated <b>progressive multifocal leukoencephalopathy </b>(PML), <b>cytomegalovirus </b>(CMV)<b> disease</b>, COVID-19, and <b>reactivation of hepatitis B (HBV) </b>or<b> hepatitis C (HCV)</b>. PVAN, primarily from activation of <b>BK virus</b>, may lead to the deterioration of kidney function and/or kidney graft loss, especially in kidney transplant recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22466913','lexi-content-ref-21940156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22466913','lexi-content-ref-21940156'])">Ref</a></span>). CMV infection may result in GI effects (eg, diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27502733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27502733'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism unknown; related to pharmacologic action. Mycophenolate is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) which results in decreased production of guanosine nucleotides in both B and T lymphocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31332670','lexi-content-ref-19497072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31332670','lexi-content-ref-19497072'])">Ref</a></span>). While some evidence exists that suggests a relationship between the degree of mycophenolate exposure (eg, dose, total mycophenolate AUC, free mycophenolate AUC, metabolite(s) AUC, trough concentrations) and the risk of infections, data are inconclusive to support a consistent relationship (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18668650','lexi-content-ref-32567256','lexi-content-ref-31332670','lexi-content-ref-15518748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18668650','lexi-content-ref-32567256','lexi-content-ref-31332670','lexi-content-ref-15518748'])">Ref</a></span>). In addition, the impact of transplantation and/or other disease processes must be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23758434','lexi-content-ref-25836768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23758434','lexi-content-ref-25836768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied. In general, the onset of infections following solid organ transplant varies greatly; the majority of clinically important infections occur within the first 180 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23464993','lexi-content-ref-11859257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23464993','lexi-content-ref-11859257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of other immunosuppressive agents or preexisting immune function impairment</p>
<p style="text-indent:-2em;margin-left:6em;">• Increased mycophenolate exposure; <b>Note:</b> Data are inconclusive to support a consistent relationship (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31332670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31332670'])">Ref</a></span>). There is a high amount of inter- and intrapatient variability with mycophenolate pharmacokinetics due to differences in formulations; gastric pH fluctuations; genetics (eg, UGT-glucuronosyltransferases, transporters); renal and hepatic function; enterohepatic recirculation; etc (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31332670','lexi-content-ref-31062373','lexi-content-ref-26082342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31332670','lexi-content-ref-31062373','lexi-content-ref-26082342'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• CMV infection:</i> Transplant recipients that are CMV seronegative at the time of transplant who receive a graft from a CMV-seropositive donor</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lymphoproliferative disorders</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In general, use of immunosuppressive agents may result in an increased risk of <b>lymphoproliferative disorders</b> and/or <b>neoplasms </b>(including <b>skin carcinoma</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23541274','lexi-content-ref-28152659','lexi-content-ref-26980727','lexi-content-ref-19897521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23541274','lexi-content-ref-28152659','lexi-content-ref-26980727','lexi-content-ref-19897521'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Some data suggest that mycophenolate may not be associated with an increased risk of post-transplant lymphoproliferative disorder (PTLD); one case-control study found that risk for PTLD was similar in kidney transplant recipients treated with triple immunosuppressive therapy with or without mycophenolate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16314782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16314782'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism unknown; related to the pharmacologic action. Mycophenolate is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) which results in decreased production of guanosine nucleotides in both B and T lymphocytes; its effect appears to be more selective on T-lymphocytes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23541274','lexi-content-ref-31332670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23541274','lexi-content-ref-31332670'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; onset of PTLD generally occurs months to years post-transplant; the incidence may be highest in the first year post-transplant when immunosuppressive therapy is most aggressive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17049061','lexi-content-ref-16314782','lexi-content-ref-16436959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17049061','lexi-content-ref-16314782','lexi-content-ref-16436959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Intensity of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23541274','lexi-content-ref-26980727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23541274','lexi-content-ref-26980727'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Concomitant use of other immunosuppressive agents or preexisting immune function impairment</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> EBV-seronegative transplant recipients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17049061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17049061'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note</b>: In general, pediatric transplant recipients are at a higher risk of PTLD as these patients are more likely to be EBV seronegative at transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10532541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10532541'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- <b>Note</b>: Clinicians may also consider the role that EBV acute infection and/or reactivation may play in the risk of EBV-associated lymphoma in patients receiving immunosuppressive therapies; risk not well defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31467148','lexi-content-ref-30728897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31467148','lexi-content-ref-30728897'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Pretransplant malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16314782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16314782'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Fewer HLA matches (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16314782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16314782'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> History of at least 1 prior rejection episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16314782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16314782'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Age &lt;25 years or &gt;60 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17049061','lexi-content-ref-16436959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17049061','lexi-content-ref-16436959'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• Skin carcinoma: </i>Exposure to sunlight/UV light</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pure red cell aplasia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pure red cell aplasia</b> (PRCA), a type of anemia which can range from subclinical to severe, has been reported in patients receiving mycophenolate concomitantly with other immunosuppressive agents (eg, tacrolimus, cyclosporine, corticosteroids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10752755','lexi-content-ref-17640860','lexi-content-ref-11127313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10752755','lexi-content-ref-17640860','lexi-content-ref-11127313'])">Ref</a></span>). Symptoms may include fatigue, lethargy, or pallor. Occurrence of PRCA may warrant treatment interruption, dosage adjustment, or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17640860','lexi-content-ref-11127313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17640860','lexi-content-ref-11127313'])">Ref</a></span>); the risk of reduced immunosuppression and graft rejection should be considered in transplant recipients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17640860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17640860'])">Ref</a></span>); the impact of concurrent disease processes (eg, parvovirus B19 infection) should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11127313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11127313'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10752755','lexi-content-ref-17640860','lexi-content-ref-11127313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10752755','lexi-content-ref-17640860','lexi-content-ref-11127313'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of other immunosuppressive agents or preexisting immune function impairment</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F198651"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults. Incidences include concomitant use with cyclosporine and corticosteroids. In general, lower doses used in renal rejection patients had less adverse effects than higher doses. Rates of adverse effects were similar for each indication, except for those unique to the specific organ involved.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (17% to 68%), hypertension (18% to 79%), hypotension (34%), lower extremity edema (16%), tachycardia (22% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (3% to 20%), ecchymoses (20%), skin rash (26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis (3% to 20%), hypercholesterolemia (46%), hyperglycemia (44% to 48%), hyperkalemia (22%), hyperlipidemia (10% to 12%), hyperuricemia (13%), hypocalcemia (11% to 30%), hypokalemia (9% to 37%), hypomagnesemia (20% to 39%), hypophosphatemia (9% to 11%), increased lactate dehydrogenase (24%), weight loss (3% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (14% to 63%)<span class="lexi-table-link-container"> (<a aria-label="Abdominal Pain table link" class="lexi-table-link" data-table-id="lexi-content-abdominal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abdominal-pain')">table 1</a>)</span><span class="table-link" style="display:none;">Abdominal Pain</span>, constipation (38% to 44%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 2</a>)</span><span class="table-link" style="display:none;">Constipation</span>, decreased appetite (25%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Appetite table link" class="lexi-table-link" data-table-id="lexi-content-decreased-appetite" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-appetite')">table 3</a>)</span><span class="table-link" style="display:none;">Decreased Appetite</span>, diarrhea (24% to 53%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 4</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, dyspepsia (19% to 23%)<span class="lexi-table-link-container"> (<a aria-label="Dyspepsia table link" class="lexi-table-link" data-table-id="lexi-content-dyspepsia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dyspepsia')">table 5</a>)</span><span class="table-link" style="display:none;">Dyspepsia</span>, esophagitis (3% to 20%), flatulence (10% to 13%), gastric ulcer (3% to 20%), gastritis (3% to 20%), gastrointestinal hemorrhage (3% to 20%), hernia of abdominal cavity (3% to 20%), intestinal obstruction (3% to 20%), nausea (27% to 56%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 6</a>)</span><span class="table-link" style="display:none;">Nausea</span>, stomatitis (3% to 20%), vomiting (20% to 39%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 7</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abdominal Pain" frame="border" id="lexi-content-abdominal-pain" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Abdominal Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day or 3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">991</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">326</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.44 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">63%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.44 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Appetite" frame="border" id="lexi-content-decreased-appetite" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Decreased Appetite</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">53%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day or 3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">991</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">326</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.44 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dyspepsia" frame="border" id="lexi-content-dyspepsia" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Dyspepsia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.44 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption>
<b>Mycophenolate: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">56%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.44 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">55%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.44 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (3% to 20%), urinary tract infection (29% to 33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (20% to 45%)<span class="lexi-table-link-container"> (<a aria-label="Anemia table link" class="lexi-table-link" data-table-id="lexi-content-anemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anemia')">table 8</a>)</span><span class="table-link" style="display:none;">Anemia</span>, benign skin neoplasm (3% to 20%), disorder of hemostatic components of blood (3% to 20%), leukocytosis (22% to 43%), leukopenia (19% to 46%)<span class="lexi-table-link-container"> (<a aria-label="Leukopenia table link" class="lexi-table-link" data-table-id="lexi-content-leukopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-leukopenia')">table 9</a>)</span><span class="table-link" style="display:none;">Leukopenia</span>, neoplasm (3% to 20%), pancytopenia (3% to 20%), skin carcinoma (3% to 20%; non-melanoma: 1% to 12%), thrombocytopenia (24% to 38%)<span class="lexi-table-link-container"> (<a aria-label="Thrombocytopenia table link" class="lexi-table-link" data-table-id="lexi-content-thrombocytopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-thrombocytopenia')">table 10</a>)</span><span class="table-link" style="display:none;">Thrombocytopenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anemia" frame="border" id="lexi-content-anemia" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Anemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">45%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">47%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.44 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day or 3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">991</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">326</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">53%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Leukopenia" frame="border" id="lexi-content-leukopenia" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Leukopenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">43%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day or 3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">991</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">326</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">210</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1.44 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Delayed release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">213</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">46%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Thrombocytopenia" frame="border" id="lexi-content-thrombocytopenia" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Thrombocytopenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (3% to 20%), increased liver enzymes (25%), increased serum alkaline phosphatase (3% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacterial infection (27% to 40%)<span class="lexi-table-link-container"> (<a aria-label="Bacterial Infection table link" class="lexi-table-link" data-table-id="lexi-content-bacterial-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bacterial-infection')">table 11</a>)</span><span class="table-link" style="display:none;">Bacterial Infection</span>, cytomegalovirus disease (4% to 22%), fungal infection (11% to 12%), viral infection (31%; including COVID-19)<span class="lexi-table-link-container"> (<a aria-label="Viral Infection table link" class="lexi-table-link" data-table-id="lexi-content-viral-infection" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-viral-infection')">table 12</a>)</span><span class="table-link" style="display:none;">Viral Infection</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bacterial Infection" frame="border" id="lexi-content-bacterial-infection" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Bacterial Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 g/day or 3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Kidney transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">991</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">326</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Liver transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">277</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">287</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Viral Infection" frame="border" id="lexi-content-viral-infection" rules="all">
<caption style="text-align:center;">
<b>Mycophenolate: Adverse Reaction: Viral Infection</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Azathioprine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mycophenolate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Azathioprine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 g/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Heart transplant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (3% to 20%), confusion (3% to 20%), depression (20%), dizziness (34%), drowsiness (3% to 20%), headache (11% to 59%), hypertonia (3% to 20%), insomnia (24% to 52%), malaise (3% to 20%), myasthenia (3% to 20%), pain (25% to 79%), paresthesia (3% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (7% to 11%), asthenia (35% to 49%), back pain (6% to 12%), tremor (12% to 34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (37%), increased serum creatinine (10% to 42%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (41%), dyspnea (31% to 44%), pleural effusion (34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (13% to 56%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Exacerbation of hypertension (&lt;10%), peripheral edema (&lt;10%), phlebitis (4%), thrombosis (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (&lt;10%), pruritus (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (&lt;10%), gastroesophageal reflux disease (&lt;10%), gingival hyperplasia (&lt;10%), oral candidiasis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocele (&lt;10%), lymphoproliferative disorder (≤1%), malignant lymphoma (1%), malignant neoplasm (≤2%), severe neutropenia (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (6% to 8%), herpes zoster infection (4% to 5%), infection (&lt;10%; implant), influenza (&lt;10%), sepsis (2% to 5%), wound infection (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (&lt;10%), fatigue (&lt;10%), peripheral pain (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (&lt;10%), myalgia (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency (&lt;10%), renal tubular necrosis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea on exertion (&lt;10%), nasopharyngitis (&lt;10%), pneumonia (&lt;10%), sinusitis (&lt;10%), upper respiratory tract infection (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hemorrhagic colitis, hemorrhagic gastritis, mucocutaneous candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Protozoal infection</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis, respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Endocarditis (Kurnicka 2017), venous thrombosis (Cherney 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Tunnicliffe 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, colitis (Calmet 2015), duodenal ulcer (Chen 2004), esophageal ulcer (Parfitt 2008), gastrointestinal perforation (Karagun 2018), oral mucosa ulcer (Asare 2020), pancreatitis (Einollahi 2015), peritonitis, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Matsui 2010), bone marrow failure, hypogammaglobulinemia (Boddana 2011; Keven 2003; Robertson 2009), Kaposi's sarcoma (Berti 2015), lymphadenopathy (Caillard 2006; Funch 2005), lymphocytopenia (Lima 2020), pure red cell aplasia (Arbeiter 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (Weber 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (Szyper-Kravitz 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Atypical mycobacterial infection, BK virus (Accott 2012), hepatitis C (reactivation) (Husain 2002), polyomavirus infection (Accott 2012), reactivation of HBV (Husain 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Meningitis (Kapitsinou 2004; Kluger 2009), progressive multifocal leukoencephalopathy (Neff 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteomyelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchiectasis (Boddana 2011; Rook 2006), interstitial pulmonary disease (Tull 2016), pulmonary edema, pulmonary fibrosis (Takahashi 2017), tuberculosis (Macauley 2018), wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Inflammation (acute inflammatory syndrome) (Hochegger 2006, Konon 2008)</p></div>
<div class="block coi drugH1Div" id="F198665"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to mycophenolate mofetil, mycophenolic acid, mycophenolate sodium, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate mofetil (CellCept): IV formulation is also contraindicated in patients who are allergic to polysorbate 80 (Tween).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Pregnancy; women of childbearing potential and not using highly effective contraceptive methods; women of childbearing potential not providing a pregnancy test result; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F198648"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disorders: Use caution in patients with active serious digestive system disease; patients with active peptic ulcers were not included in clinical studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoxanthine-guanine phosphoribosyltransferase deficiency: Theoretically, use should be avoided in patients with the rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (such as Lesch-Nyhan or Kelley-Seegmiller syndrome).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment as toxicity may be increased; may require dosage adjustment in severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with systemic lupus erythematosus (SLE) undergoing hip or knee replacement surgery: Patients with <b>
<i>severe</i></b> SLE (referring to patients with severe organ manifestations such as nephritis) should not interrupt therapy when undergoing hip or knee replacement surgery. For patients with SLE <b>
<i>without</i></b> severe disease<b>,</b> hold mycophenolate for at least 1 week prior to surgery to reduce infection risk; therapy can be restarted once surgical wound shows evidence of healing (eg, no swelling, erythema, or drainage), sutures/staples are removed, and no ongoing nonsurgical site infections (typically ~14 days to reduce infection risk) (ACR/AAHKS [Goodman 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Non-interchangeability of dosage forms: Mycophenolate sodium and mycophenolate mofetil should <b>not</b> be used interchangeably without health care provider supervision because the rate of absorption following the administration of these two products is not equivalent. Single dose pharmacokinetic studies in adult renal transplant recipients suggest that bioavailability is similar between oral mycophenolate mofetil (1 g) and delayed-release mycophenolic acid (720 <b>mg</b>) (Arns 2005). In clinical trials, comparative efficacy and safety profiles have been observed in adult renal transplant recipients randomized to either oral mycophenolate mofetil (1 g twice daily) or delayed-release mycophenolic acid (720 <b>mg</b> twice daily) (Budde 2004b; Salvadori 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some dosage forms may contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood donations: Patients should not donate blood or blood products during treatment and for at least 6 weeks after the last dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Myasthenia gravis: Abrupt cessation of this or any immunosuppressant, especially in clinically unstable individuals, may result in rapid deterioration of myasthenic symptoms and possibly myasthenic crisis (Melzer 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Live attenuated vaccines should be avoided during use; vaccinations may be less effective during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: IV solutions should be given over at least 2 hours; <b>never</b> administer IV solution by rapid or bolus injection.</p></div>
<div class="block foc drugH1Div" id="F198659"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as mofetil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CellCept: 250 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as mofetil hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CellCept Intravenous: 500 mg (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as mofetil hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral, as mofetil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CellCept: 200 mg/mL (160 mL) [contains aspartame, methylparaben, sorbitol, soybean lecithin; mixed fruit flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/mL (160 mL, 170 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as mofetil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CellCept: 500 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as mycophenolic acid: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myfortic: 180 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myfortic: 360 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 180 mg, 360 mg</p></div>
<div class="block geq drugH1Div" id="F198644"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F198667"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (CellCept Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $10.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Mycophenolate Mofetil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.32 - $3.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (CellCept Intravenous Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $129.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Mycophenolate Mofetil HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $49.50 - $87.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (CellCept Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/mL (per mL): $10.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Mycophenolate Mofetil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/mL (per mL): $9.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Mycophenolate Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $4.39 - $4.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $9.13 - $9.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Myfortic Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $8.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $16.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (CellCept Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $21.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Mycophenolate Mofetil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $1.14 - $20.51</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867608"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as mofetil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CellCept: 250 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as mofetil hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CellCept IV: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral, as mofetil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CellCept: 200 mg/mL (175 mL) [contains aspartame, methylparaben, soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg/mL (165 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as mofetil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CellCept: 500 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as mycophenolic acid: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myfortic: 180 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myfortic: 360 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 180 mg, 360 mg</p></div>
<div class="block adm drugH1Div" id="F198662"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May be administered with or without food as effects of food on bioavailability are minor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23475567','lexi-content-ref-8799515','lexi-content-ref-9646007','lexi-content-ref-16863458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23475567','lexi-content-ref-8799515','lexi-content-ref-9646007','lexi-content-ref-16863458'])">Ref</a></span>). Oral suspension may be administered via a nasogastric tube (minimum 8 French, 1.7 mm interior diameter); do not mix oral suspension with other medications. Delayed-release mycophenolate sodium tablets (Myfortic) should be swallowed whole and should not be crushed, cut, or chewed. If a dose is missed, administer as soon as it is remembered. If it is close to the next scheduled dose, skip the missed dose and resume at next regularly scheduled time; do not double a dose to make up for a missed dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. The release of mycophenolate sodium from the enteric coating occurs in the neutral pH of the intestine. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, clinicians should be vigilant in efficacy/side effect monitoring and consider therapeutic drug monitoring before and after surgery given that interpatient variability of mycophenolate absorption has been observed after gastric bypass (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18482049']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18482049'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> IV solutions should be administered over at least 2 hours (either peripheral or central vein); do <b>not</b> administer IV solution by rapid or bolus injection.</p></div>
<div class="block admp drugH1Div" id="F52613369"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate mofetil (CellCept): Capsule, tablet, suspension: Administer on an empty stomach to avoid variability in absorption; may be administered with food in stable patients when necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral suspension: Shake suspension well before use; may be administered via a nasogastric tube (minimum: 8 French, 1.7 mm interior diameter); oral suspension should not be mixed with other medications or liquids.</p>
<p style="text-indent:-2em;margin-left:6em;">Capsules and tablets: Swallow whole; do not crush or open.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed dose</i>: If a dose is missed, administer as soon as it is remembered. If it is close to the next scheduled dose (within 2 hours), skip the missed dose and resume at next regularly scheduled time; do not double a dose to make up for a missed dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate sodium (Myfortic): Delayed-release tablet: Administer on an empty stomach 1 hour before or 2 hours after food to avoid variability in absorption. Swallow whole; do not crush, chew, or cut.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: <b>Do not administer IV push</b> or by rapid IV bolus injection; administer by slow IV infusion over a period of no less than 2 hours.</p></div>
<div class="block hazard drugH1Div" id="F49132818"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F7874743"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Myfortic: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F050791s035lbl.pdf%23page%3D23&amp;token=DSuVtHE2viX7gt4ayXOWx1r8YckdMZevYb1sv1UmgwQUuQF9xQLUtk%2B3Ci6WbaTsM1EN3Q3ZPOyawiKLt6KeAEqU6BbLNTUVDoGykFoU9bTk4OGMOIOrWkfRYcPlczVJ&amp;TOPIC_ID=9670" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050791s035lbl.pdf#page=23</a></p>
<p style="text-indent:-2em;margin-left:4em;">CellCept: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F050722s049s051%2C050723s049s051%2C050758s047s049lbl.pdf%23page%3D39&amp;token=w%2BiVT7stw1yVbdW%2BhSobqgYfhiNfBeF8ymN%2Fc9ZFcVyBcDsJTItfXpzFJ3b%2FoJatjnTlmwn23645CvgmsWDoxTa7FTiq1JSGiC2CQSzdR0rUBMw0uk%2BXROfFyoXnGVYvdnpACeJ3bVc%2FKIIOfhbPDA%3D%3D&amp;TOPIC_ID=9670" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050722s049s051,050723s049s051,050758s047s049lbl.pdf#page=39</a></p></div>
<div class="block use drugH1Div" id="F198660"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Organ transplantation:</b> Prophylaxis of organ rejection in patients receiving allogeneic renal (mycophenolate mofetil [CellCept], mycophenolate sodium, delayed release [Myfortic]), cardiac (mycophenolate mofetil), or liver (mycophenolate mofetil) transplants, in combination with other immunosuppressants.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> While traditionally used in combination with cyclosporine, mycophenolate is now used primarily in combination with tacrolimus and, to a lesser extent, with a mammalian target of rapamycin inhibitor (everolimus or sirolimus) for prophylaxis of rejection in renal, cardiac, and hepatic transplants (AASLD/AST [Lucey 2013]; Aliabadi 2012; Eisen 2013; Groetzner 2009; Guethoff 2013; ISHLT [Costanzo 2010]; KDIGO [Chapman 2010]).</p></div>
<div class="block off-label drugH1Div" id="F25469168"><span class="drugH1">Use: Off-Label: Adult</span><p>Bullous pemphigoid; Dermatomyositis (cutaneous), refractory; Discoid lupus and subacute cutaneous lupus, refractory; Eosinophilic granulomatosis with polyangiitis (Churg-Strauss); Focal segmental glomerulosclerosis, glucocorticoid-dependent or glucocorticoid-resistant; Graft-vs-host disease in allogeneic hematopoietic cell transplantation; Granulomatosis with polyangiitis and microscopic polyangiitis; Heart transplantation, maintenance immunosuppressive therapy; Hepatitis, autoimmune, refractory; IgA nephropathy, primary, nonvariant; Interstitial nephritis, acute; Interstitial pneumonia/interstitial lung disease; Liver transplantation, maintenance immunosuppressive therapy; Lung transplantation, maintenance immunosuppressive therapy; Lupus nephritis, focal or diffuse; Minimal change disease; Myasthenia gravis, chronic immunosuppressive therapy; Pemphigus vulgaris and pemphigus foliaceus; Systemic sclerosis (scleroderma); Takayasu arteritis; Toxicities associated with immune checkpoint inhibitor therapy, treatment; Uveitis, noninfectious</p></div>
<div class="block mst drugH1Div" id="F25708052"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299731"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3, OATP1B1/1B3 (SLCO1B1/1B3), UGT1A10, UGT1A8, UGT1A9, UGT2B7</p></div>
<div class="block dri drugH1Div" id="F198653"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acyclovir-Valacyclovir: May increase the serum concentration of Mycophenolate. Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: May decrease the serum concentration of Mycophenolate. Management: Simultaneous administration of aluminum hydroxide antacids with the Myfortic brand of mycophenolic acid is not recommended. Administrater aluminum hydroxide at least 2 hours after a dose of the Cellcept brand of mycophenolate mofetil.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Mycophenolate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholestyramine Resin: May decrease the serum concentration of Mycophenolate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Mycophenolate may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Rheumatology guidelines recommend holding mycophenolate for 1 to 2 weeks after each vaccine dose as permitted by the underlying disease. This recommendation is specific to patients using mycophenolate for rheumatic and musculoskeletal diseases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid. Management: Mycophenolate requirements may be greater in patients receiving cyclosporine. Monitor mycophenolate dosing and response to therapy particularly closely when adjusting concurrent cyclosporine (starting, stopping, or changing dose).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: Mycophenolate may enhance the adverse/toxic effect of Ganciclovir-Valganciclovir. Specifically, the risk for leukopenia or neutropenia may be increased with this combination. Mycophenolate may increase the serum concentration of Ganciclovir-Valganciclovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Mycophenolate may decrease the serum concentration of Hormonal Contraceptives.  Management: Patients of childbearing potential who are taking hormonal contraceptives should use an additional form of barrier contraception during treatment with mycophenolate and for 6 weeks after mycophenolate discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: May increase the serum concentration of Mycophenolate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Hydroxide: May decrease the serum concentration of Mycophenolate. Management: Simultaneous administration of magnesium hydroxide antacids with the Myfortic brand of mycophenolic acid is specifically not recommended. Administer magnesium hydroxide at least 2 hours after a dose of the Cellcept brand of mycophenolate mofetil.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Patiromer: May decrease the serum concentration of Mycophenolate. Management: Administer mycophenolate at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: May decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Mycophenolate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease serum concentrations of the active metabolite(s) of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be decreased. Management: Avoid concurrent use of rifampin and mycophenolate when possible. If used together, closely monitor mycophenolic acid levels and clinical response. Mycophenolate doses may need to be increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sevelamer: May decrease the serum concentration of Mycophenolate. Management: Administer mycophenolate at least 2 hours prior to sevelamer administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F198682"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases C<sub>max</sub> of MPA by 40% following mycophenolate mofetil (CellCept) administration and 33% following mycophenolate sodium (Myfortic) use; the extent of absorption is not changed. Management: Take mycophenolate mofetil or mycophenolate sodium on an empty stomach to decrease variability; however, mycophenolate mofetil may be taken with food if necessary in stable renal transplant recipients.</p></div>
<div class="block rep_considerations drugH1Div" id="F49308478"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: Females of reproductive potential must be counseled regarding pregnancy prevention and planning.</b> Pregnancy testing, prevention, and planning must be discussed with all females of reproductive potential and male patients with female partners of reproductive potential. Alternative agents should be used whenever possible in patients planning a pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Females of reproductive potential (girls who have entered puberty and women with a uterus who have not passed through clinically confirmed menopause) should have a negative pregnancy test with a sensitivity of ≥25 milliunits/mL immediately before mycophenolate therapy and the test should be repeated 8 to 10 days later. Pregnancy tests should then be repeated during routine follow-up visits. Acceptable forms of contraception should be used during treatment and for 6 weeks after therapy is discontinued. An intrauterine device, tubal sterilization, or vasectomy of the female patient's partner are acceptable contraceptive methods that can be used alone. If a hormonal contraceptive is used (eg, combination oral contraceptive pills, transdermal patches, vaginal rings, or progestin only products), then one barrier method must also be used (eg, diaphragm or cervical cap with spermicide, contraceptive sponge, male or female condom). Alternatively, the use of 2 barrier methods is also acceptable (eg, diaphragm or cervical cap with spermicide, or contraceptive sponge <b>PLUS</b> male or female condom). Refer to manufacturer's labeling for full details. The effectiveness of hormonal contraceptive agents may be affected by mycophenolate.</p>
<p style="text-indent:0em;margin-top:2em;">Mycophenolate has been used as an immunosuppressant in patients undergoing uterine transplant (limited data); mycophenolate is discontinued and changed to a different agent prior to embryo transfer (Jones 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Mycophenolate should be discontinued, and therapy changed to an appropriate immunosuppressant prior to conception in kidney, liver, and heart transplant recipients who are planning a pregnancy (AASLD [Lucey 2013]); EBPG 2002; ISHLT [Costanzo 2010]; KDIGO 2009; López 2014). Mycophenolate should also be discontinued prior to conception in females treated for other indications who are planning a pregnancy. The Risk Evaluation and Mitigation Strategy (REMS) program recommends discontinuing mycophenolate in females at least 6 weeks before pregnancy is attempted. However, due to the potential for disease flare following discontinuation, women treated for rheumatic and musculoskeletal diseases should consider discontinuing mycophenolate 3 to 6 months prior to attempted pregnancy to allow for disease monitoring and potential change to another immunosuppressant (ACR [Sammaritano 2020]). Women taking mycophenolate for myasthenia gravis are recommended to discontinue therapy at least 4 months prior to planning a pregnancy (Sanders 2016).</p>
<p style="text-indent:0em;margin-top:2em;">When mycophenolate is used for the treatment of rheumatic and musculoskeletal diseases in women undergoing ovarian stimulation for oocyte retrieval or embryo cryopreservation, mycophenolate may be continued in patients whose condition is stable and discontinuation of treatment may lead to uncontrolled disease (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the mycophenolate and male fertility or pregnancy outcomes following paternal use is limited; however, available data have not suggested safety concerns (Bermas 2019; Mouyis 2019). According to the manufacturer, sexually active male patients and/or their female partners should use effective contraception during treatment of the male patient and for at least 90 days after last dose. In addition, males should not donate semen during mycophenolate therapy and for 90 days following the last mycophenolate dose (recommendation based on animal data). However, use of mycophenolate may be considered for males with rheumatic and musculoskeletal diseases who are planning to father a child (recommendation based on limited human data) (ACR [Sammaritano 2020]; Midtvedt 2017).</p></div>
<div class="block pri drugH1Div" id="F198668"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. </b></p>
<p style="text-indent:0em;margin-top:2em;">Congenital malformations have been reported in 23% to 27% of live births following exposure to mycophenolate during pregnancy. Birth defects include facial malformations (cleft lip, cleft palate, micrognathia, hypertelorism of the orbits); ear and eye abnormalities (abnormally formed or absent external/middle ear, coloboma, microphthalmos); finger malformations (brachydactyly, polydactyly, syndactyly); cardiac abnormalities (atrial and ventricular septal defects); esophageal malformations (esophageal atresia); and CNS malformations (spina bifida). The combination of ear, eye, and lip/palate abnormalities has been identified as mycophenolate embryopathy (Perez-Aytes 2017). The risk of first trimester pregnancy loss may be 45% to 49% following mycophenolate exposure.</p>
<p style="text-indent:0em;margin-top:2em;">Mycophenolate is not an acceptable immunosuppressant for use in patients who become pregnant following a kidney (EBPG 2002; KDIGO 2009; López 2014), liver (AASLD [Lucey 2013]), or heart (ISHLT [Costanzo 2010]) transplant. In addition, mycophenolate should not be used for the treatment of autoimmune hepatitis (AASLD [Mack 2020]), myasthenia gravis (Sanders 2016), or rheumatic and musculoskeletal diseases (ACR [Sammaritano 2020]) during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to mycophenolate is ongoing. Health care providers should report female exposures to mycophenolate during pregnancy or within 6 weeks of discontinuing therapy to the Mycophenolate Pregnancy Registry (800-617-8191).</p>
<p style="text-indent:0em;margin-top:2em;">The Transplant Pregnancy Registry International (TPR) is a registry that follows pregnancies that occur in maternal transplant recipients or those fathered by male transplant recipients. The TPR encourages reporting of pregnancies following solid organ transplant by contacting them at 1-877-955-6877 or https://www.transplantpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F198669"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if mycophenolate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Adverse events were not observed in 7 infants born between 34 and 40 weeks' gestation and exposed to mycophenolate via breast milk for up to 14 months. However, due to the long half-life and lack of information related to mycophenolate and breastfeeding, breastfeeding is not recommended by some guidelines (ACR [Sammaritano 2020]; Constantinescu 2014; López 2014).</p></div>
<div class="block dic drugH1Div" id="F198670"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F198657"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Complete blood count (weekly for first month, twice monthly during months 2 and 3, then monthly thereafter through the first year); renal and liver function; signs and symptoms of organ rejection; signs and symptoms of bacterial, fungal, protozoal, new or reactivated viral (including reactivation of HBV or HCV), or opportunistic infections; neurological symptoms (eg, hemiparesis, confusion, cognitive deficiencies, ataxia) suggestive of progressive multifocal leukoencephalopathy; in patients with hepatitis B or hepatitis C, monitor for signs of viral reactivation; monitor for signs/symptoms (eg, fever, arthralgias, arthritis, muscle pain, proinflammatory markers) suggestive of acute inflammatory syndrome; pregnancy test (sensitivity of ≥25 milliunits/mL; immediately prior to initiation and 8 to 10 days later in patients who may become pregnant, followed by repeat tests during therapy); monitor skin (for lesions suspicious of skin cancer); monitor for signs of lymphoma; monitor for signs of pure red cell aplasia or autoimmune hemolytic anemia (Elimelakh 2007; Hodo 2006; Schecter 2007).</p></div>
<div class="block rer drugH1Div" id="F51340749"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Routine monitoring of mycophenolate levels is not recommended (Chapman 2010; ISHLT [Costanzo 2010]). Therapeutic drug monitoring may be beneficial in patients with high risk for rejection or increased adverse effects (Roan 2013; van Gelder 2006; Zuk 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolic acid (MPA) trough levels are poorly correlated with AUC and are not recommended (Arns 2006). Two abbreviated AUC<sub>0-12 </sub>equations have been shown to correlate with a full AUC measurement (Pawinski 2002; Tutor-Crespo 2009). These estimations have only been validated in patients receiving mycophenolate mofetil (CellCept) at steady-state using total MPA (tMPA) concentrations and should not be used for patients receiving mycophenolate sodium (Myfortic). Because MPA is highly protein bound, caution should be used in patients with severe renal impairment, high bilirubin, and low albumin; in this population, free MPA (fMPA) levels may be of more value (van Gelder 2006).</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<i>Three sample model equation:</i></p>
<p style="text-indent:-2em;margin-left:6em;">7.75 + 6.49*C<sub>0H</sub> + 0.76*C<sub>0.5H</sub> + 2.43*C<sub>2H</sub></p>
<p style="text-indent:-2em;margin-left:6em;">Where C<sub>0H</sub> is the concentration tMPA at 0 hours (time dose is administered) and C<sub>0.5H</sub>, C<sub>2H</sub> are the tMPA levels 0.5 and 2 hours after the dose, respectively (Pawinski 2002).</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<i>Two sample model equation:</i></p>
<p style="text-indent:-2em;margin-left:6em;">11.55 + 7.25*C<sub>0H </sub>+ 3.35*C<sub>2H</sub></p>
<p style="text-indent:-2em;margin-left:6em;">Where C<sub>0H</sub> is the tMPA level at 0 hours (time dose is administered) C<sub>2H</sub> is the tMPA level 2 hours after the dose (Tutor-Crespo 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Goal MPA AUC is ~30 to 60 mcg*hour/mL. Levels &lt;30 have been associated with an increased risk of rejection; however, the upper limit of 60 has not been well defined, nor have MPA AUC been correlated with toxicities or adverse effects (van Gelder 2006).</p></div>
<div class="block pha drugH1Div" id="F198647"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">MPA exhibits a cytostatic and reversible effect on T and B lymphocytes. It is an inhibitor of type I and type II inosine monophosphate dehydrogenase (IMPDH) which inhibits <i>de novo</i> guanosine nucleotide synthesis and blocks DNA synthesis. MPA shifts transcriptional activities in human CD4+ T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways, causing the T-cells to become less responsive to antigenic stimulation. MPA enhances the expression of negative costimulators such as CD70, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreasing the expression of positive costimulators CD27 and CD28. T and B lymphocytes are dependent on this pathway for proliferation. MPA helps in the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-γ, IL-17, and TNF-α. MPA also prevents glycosylation of lymphocyte and monocyte glycoproteins involved in intercellular adhesion to endothelial cells and can inhibit leukocytes into sites of inflammation and graft rejection.</p></div>
<div class="block phk drugH1Div" id="F198664"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Peak effect: Correlation of toxicity or efficacy is still being developed; however, one study indicated that 12-hour AUCs &gt;40 mcg/mL/hour were correlated with efficacy and decreased episodes of rejection.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and extensive; early post-transplant period mycophenolic acid (MPA) AUC values are lower (~45% to 53%) than later post-transplant period (&gt;3 months) MPA AUC values in both pediatric patients and adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Mycophenolate sodium, delayed release: 93%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate mofetil: MPA: ~3.6 ± 1.5 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate sodium, delayed release: MPA: Oral: 54 L (at steady state); 112 L (elimination phase).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: MPA: 97%; glucuronidated MPA (MPAG): 82%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic and via GI tract; mycophenolate mofetil is completely hydrolyzed in the liver to mycophenolic acid (MPA; active metabolite); enterohepatic recirculation of MPA may occur; MPA is glucuronidated to MPAG (inactive metabolite).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Mycophenolate mofetil: 94% (oral MMF relative to IV MMF); enterohepatic recirculation contributes to MPA concentration (Staatz 2007); two 500 mg tablets have been shown to be bioequivalent to four 250 mg capsules or 1,000 mg of oral suspension; Mycophenolate sodium, delayed release: 72%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate mofetil: MPA: Oral: 17.9 ± 6.5 hours; IV: 16.6 ± 5.8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate sodium, delayed release: MPA: Oral: 8 to 16 hours; MPAG: 13 to 17 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: MPA:</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate mofetil: Single dose, healthy volunteers (1 g): 0.8 hours; Steady state, solid organ transplant recipients (1 to 1. 5 g twice daily): 0.9 to 1.8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate sodium, delayed release: Single dose (720 mg): 2 hours (range: 0.8 to 8 hours); Steady state (720 mg twice daily): 1.5 to 2.5 hours (range: 0 to 8 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate mofetil: MPA: Urine (&lt;1%), feces (6%); MPAG: Urine (87%).</p>
<p style="text-indent:-2em;margin-left:4em;">Mycophenolate sodium, delayed release: MPA: Urine (3%), feces; MPAG: Urine (&gt;60%).</p></div>
<div class="block phksp drugH1Div" id="F51159698"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mycophenolate mofetil: Mycophenolic acid AUC increased 75%, and mycophenolic acid glucuronide AUC increased 3- to 6-fold in patients with severe renal impairment (glomerular filtration rate [GFR] &lt;25 mL/minute/1.73 m<sup>2</sup>).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F198671"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Lamucon | Mofetab | Myfortic | Mytox | Zenocept</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Metocris | Micofenolato mofetil varifarma | Mmf sandoz | Myfortic | Suprimun</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycophenolat mofetil sandoz | Mycophenolate mofetil accord | Mycophenolatmofetil accord | Mycophenolatmofetil actavis | Mycophenolatmofetil medico uno | Mycophenolatmofetil stada | Mycophenolsaeure Accord Healthcare | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo mycophenolate | Cellcept | Cellplant | Ceptolate | Imulate | Mycocept | Mycophenolate Accord | Mycophenolate an | Mycophenolate gh | Mycophenolate sandoz | Myfortic | Pharmacor mycophenolate</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Origano | Phenocept</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycophenolat mofetil sandoz | Mycophenolate mofetil accord | Mycophenolate mofetil actavis | Mycophenolate mofetil mylan | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycophenolate Accord | Mycophenolate mofetil accord | Mycophenolate mofetil actavis | Myfenax | Myfortic | Suprephen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Micof Mofetila | Micofenolato de mofetila | Micofenolato de sodio | Micofenolato mofetil g | Mofecell | Mofilen | Myfortic | Myyko lr</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycophenolat mepha | Mycophenolat mofetil sandoz | Mycophenolat mofetil teva | Myfortic</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Myfortic</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Inmufen | Lamucon | Micofenolato mofetilo | Myfortic | Profiren | Suprimun</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Fu yi | Pu jin | Sai ke ping | Su neng | Xiao xi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Felonex | Inmukem | Linfonex | Micofenolato | Micofenolato de mofetilo | Micofenolato mofetil | Micofenolato mofetilo | Micoflavin | Mycokem | Mycotas | Myfetil | Myfortic | Mymobex | Tecnozida</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Myclausen | Mycofenolat Actavis | Mycofenor | Mycophenolat mofetil sandoz | Mycophenolate mofetil Apotex | Mycophenolate mofetil mylan | Mycophenolate stada | Mycophenolic acid | Myfenax | Mygref</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Myclausen | Mycopheno | Mycophenolat 1A pharma | Mycophenolat mofetil accord | Mycophenolat mofetil tillomed | Mycophenolate mofetil accord | Mycophenolatmofetil actavis | Mycophenolatmofetil AL | Mycophenolatmofetil ascend | Mycophenolatmofetil heumann | Mycophenolatmofetil hexal | Mycophenolatmofetil tillomed | Mycophenolatmofetil Winthrop | Mycophenolsaeure Accord | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Linfonex | Micofenolato de mofetilo sandoz | Micofenolato mofetilo | Micoflavin | Mofilet | Myfortic | Refrat</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Fenomic | Linfonex | Micoflavin | Myfortic</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycophenolate mofetil sandoz | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Ceptolate | Myfortic</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acido micofenolico accord | Cellcept | Ceptava | Micofenolato de mofetilo accord | Micofenolato de mofetilo actavis | Micofenolato de mofetilo aristo | Micofenolato de mofetilo cinfa | Micofenolato de mofetilo combix | Micofenolato de mofetilo kern | Micofenolato de mofetilo mylan | Micofenolato de mofetilo sandoz | Micofenolato de mofetilo tecnigen | Micofenolato de mofetilo ur | Micofenolato mofetilo actavis | Micofenolato Mofetilo Normon | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Myfortic</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Myastad | Myclausen | Mycophen mofetil Sandoz | Mycophen mofetil Stada | Mycophenolate mofetil accord | Mycophenolate Mofetil Arrow | Mycophenolate mofetil Orion | Myfenax | Myfortic | Mykofenolatmofetil | Mykofenolatmofetil Mylan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycophenolate mofetil accord healthcare | Mycophenolate mofetil actavis | Mycophenolate Mofetil Arrow | Mycophenolate mofetil biogaran | Mycophenolate mofetil eg | Mycophenolate mofetil mylan | Mycophenolate mofetil mylan pharma | Mycophenolate mofetil Ranbaxy | Mycophenolate mofetil ratiopharm | Mycophenolate mofetil sandoz | Mycophenolate mofetil teva | Mycophenolate mofetil winthrop | Mycophenolate mofetil zydus | Myfortic</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arzip | Cellcept | Ceptava | Mycophenolate | Mycophenolate mofetil | Mycophenolate mofetil sandoz | Mycophenolate mofetil teva | Mycophenolate mofetil tillomed | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Myclausen | Myfenax | Myfetil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Micocept | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Myfortic | Trixin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mofimutral | Mycophenolate mofetil actavis | Mycophenolate mofetil medico uno | Myfenax | Presumin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Celmunos | Myfortic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycolat | Mycophenolate | Mycophenolate mofetil accord | Mycophenolate mofetil mylan | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Myfortic</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ancept | Baxmune | Biomyf | Cellcept | Cellmune | Emcept | Fenograf | Fenograf s | Graftide m | Graftide s | Immutil | Immutil s | Jbmune | Keycept | Keycept s | Mmf | Mofetyl s | Moficept | Moficept s | Mofilet | Mofilet-s | My360 | Mycept | Mycocept | Mycofit | Mycofit-s | Mycophen | Mycophen s | Mycoral | Mycosan m | Mycosan-s | Mycotil | Myfortic | Myotec | Myotec s | Myplat | Phenolate | Phenolate s | Picept | Renfor | Renodapt | Renofix M | Renofix S | Seromune</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Myfenax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acido micofenolico accord | Cellcept | Ceptava | Micofenolato mofetile | Micofenolato mofetile accord | Micofenolato Mofetile Actavis | Micofenolato Mofetile Crinos | Micofenolato mofetile mylan generics | Micofenolato mofetile sandoz | Micofenolato mofetile tillomed | Myfenax</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cellcept</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cellcept</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mofecon | Mofecon c | Mofecon s | Mofetyl | Mofilet | Mphetas | Mycept | Mycofet | Mycokem | Myfortic | Renodapt</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Immucept | My rept | Mycocept | Myconol | Myfortic | Myrept | Myreptic n | Sandoz mycophenolate | Unicept</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cellcept</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Imunocell | Imuxgen | Lamucon | Mmf | Mofetab | Myfortic | Myora</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycofenor | Mycophen mofetil accord | Mycophenolate mofetil accord | Mycophenolate mofetil Ranbaxy | Myfortic</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycofenor | Mycofit | Mycophenolate mofetil accord | Mycophenolate mofetil Ranbaxy | Mycophenolate mofetil sandoz | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cellcept</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Accocept | Biostger | Cellcept | Celprot | Espeflun | Femulan | Kofetil | Lanfetil | Myfortic | Tevacept | Zel amsa | Zurebid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycofit | Myfortic | Refrat</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Mofilet | Myfortic</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycofenolaat mofetil | Mycofenolaat Mofetil Accord | Mycofenolaat mofetil Actavis | Mycofenolaat mofetil Apotex | Mycofenolaat mofetil Mylan | Mycofenolaat mofetil ratiopharm | Mycofenolaat mofetil Sandoz | Mycofenolaatmofetil actavis | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycophenolatemofetil accord | Mycophenolatemofetil sandoz | Myfenax | Myfortic | Mykofenolat accord | Mykofenolatmofetil | Mykofenolatmofetil Accord | Mykofenolsyre accord</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Ceptolate | Myaccord | Myfortic</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acido micofenolico | Indomet | Linfex | Micofenolato mofetilo | Micoflavin | Myfortic</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Atajec | Cellcept | Cyfen | Moferen | Mofilet | Mycept | Mycokem | Mygraft | Myotec | Renocell | Unoren</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mft | Micocept | My rept | Mycolate | Mycophenol | Myfortic | Phenolate | Suprimun</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Limfocept | Marelim | Mofimutral | Mycofenor | Mycophenolate mofetil accord | Mycophenolate mofetil Apotex | Mycophenolate mofetil Stada | Mycophenolate sandoz | Myfortic | Mykofenolan mofetylu accord | Mykofenolsyre accord</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mycophenolate mofetil | Mycophenolic acid | Myfortic</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acido micofenolico accord | Cellcept | Micofenolato de Mofetil Accord | Micofenolato de mofetil actavis | Micofenolato de mofetil aristo | Micofenolato de mofetil Generis | Micofenolato de mofetil germed | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acido micofenolico cellofarm | Acido micofenolico imedic | Acido micofenolico intas | Acido micofenolico prosalud | Acido micofenolico quimfa | Cellcept | Genesil | Indira | Linfonex | Micofenolato de mofetilo cipla | Micofenolato de mofetilo imedic | Micofenolato mofetil bioteng | Micofenolato mofetil cellofarm | Micofenolato omicron | Micofenolato sandoz | Micofenolato varifarma | Micofenolatode de sodio bioethic pharma | Micoflavin | Molifet | Mycoldosa | Myfortic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Lamucon | Melnolate | Mofetab | Myfortic</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Micofenolat mofetil Sandoz | Myfenax</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acidum Mycophenolicum TL | Cellcept | Felomika | Flomiren | Mmf | Mmf tl | Mycophenolate mofetil TL | Mycophenolate sandoz | Mycophenolate teva | Mycophenolic acid | Myfenax | Myfortic | Mysept | Nikvesel | Supresta</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Accept | Apo mycophenolate | Apo mycophenolate mofetil | Cellcept | Cellona | Lamucon | Mofetab | Myfortic | Myora</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Myclausen | Mycophen mofetil accord | Mycophenolate mofetil accord | Mycophenolate Mofetil Arrow | Mycophenolate mofetil Cross Pharma | Mycophenolate mofetil sandoz | Myfenax | Myfortic | Mykofenolatmofetil | Mykofenolatmofetil accord | Mykofenolatmofetil actavis | Mykofenolatmofetil eql | Mykofenolatmofetil orifarm | Mykofenolatmofetil stada | Mykofenolsyra Accord</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Myfortic</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mofetilmikofenolat | Mofetilmikofenolat actavis</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Mofetilmykofenolat stada | Mycofenolat Actavis | Mycofenor | Mycophenolate mofetil mylan | Myfenax | Mygref | Mykofenolat mofetil sandoz</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Immucept | Mycophenolate | Mycophenolate mofetil tecnigen | Myfortic</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Lofepal | Mefil | Mmf | Stopimmo</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Micosef | Mikocept | Mofecept | Myfortic | Tarbetax</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Immufine | Mycocep | Myfortic</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acidum mycophenolicum | Almifort | Cellcept | Cellsept | Imufet | Micomeda | Mofilet | Myfenax | Myfortic</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Mofilet | Myfortic</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Micofenolato mofetil | Myfortic | Profiren | Suprimun</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Micoflavin | Myfortic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cellcept | Cimune | Immunolate | Micomune | Mycocept | Mycokem | Mycophenolat alkem | Mycophenolate alkem | Mycophenolate ascendis | Mycophenolate teva | Myfortic</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Mofilet</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23475567">
<a name="23475567"></a>Abd Rahman AN, Tett SE, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. <i>Clin Pharmacokinet</i>. 2013;52(5):303-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23475567/pubmed" id="23475567" target="_blank">23475567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22466913">
<a name="22466913"></a>Acott P, Babel N. BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? <i>Ann Transplant</i>. 2012;17(1):86-99. doi:10.12659/aot.882640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/22466913/pubmed" id="22466913" target="_blank">22466913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22941325">
<a name="22941325"></a>Aliabadi A, Cochrane AB, Zuckermann AO. Current strategies and future trends in immunosuppression after heart transplantation. <i>Curr Opin Organ Transplant</i>. 2012;17(5):540-545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/22941325/pubmed" id="22941325" target="_blank">22941325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19443659">
<a name="19443659"></a>Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood. </i>2009;114(3):511-517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19443659/pubmed" id="19443659" target="_blank">19443659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25041227">
<a name="25041227"></a>Andreassen AK, Andersson B, Gustafsson F, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. <i>Am J Transplant</i>. 2014;14(8):1828-1838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25041227/pubmed" id="25041227" target="_blank">25041227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26835147">
<a name="26835147"></a>Anutrakulchai S, Panaput T, Wongchinsri J, et al. A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience. <i>Lupus Sci Med</i>. 2016;3(1):e000120. doi:10.1136/lupus-2015-000120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/26835147/pubmed" id="26835147" target="_blank">26835147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19369404">
<a name="19369404"></a>Appel GB, Contreras G, Dooley MA, et al; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. <i>J Am Soc Nephrol</i>. 2009;20(5):1103-1112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19369404/pubmed" id="19369404" target="_blank">19369404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20581019">
<a name="20581019"></a>Aragon E, Chan YH, Ng KH, et al. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. <i>Lupus</i>. 2010;19(8):965-973.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20581019/pubmed" id="20581019" target="_blank">20581019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10752755">
<a name="10752755"></a>Arbeiter K, Greenbaum L, Balzar E, et al. Reproducible erythroid aplasia caused by mycophenolate mofetil. <i>Pediatr Nephrol</i>. 2000;14(3):195-197. doi:10.1007/s004670050039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/10752755/pubmed" id="10752755" target="_blank">10752755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17275481">
<a name="17275481"></a>Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? <i>Transplant Proc</i>. 2007;39(1):88-93. doi:10.1016/j.transproceed.2006.10.189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17275481/pubmed" id="17275481" target="_blank">17275481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15740555">
<a name="15740555"></a>Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. <i>Clin Transplant</i>. 2005;19(2):199-206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/15740555/pubmed" id="15740555" target="_blank">15740555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17060847">
<a name="17060847"></a>Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. <i>Transplantation</i>. 2006;82(8):1004-1012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17060847/pubmed" id="17060847" target="_blank">17060847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058566">
<a name="32058566"></a>Asare K, Gatzke CB. Mycophenolate-induced oral ulcers: Case report and literature review. <i>Am J Health Syst Pharm</i>. 2020;77(7):523-528. doi:10.1093/ajhp/zxz358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/32058566/pubmed" id="32058566" target="_blank">32058566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15030353">
<a name="15030353"></a>Assaf C, Mewis G, Orfanos CE, Geilen CC. Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. <i>Br J Dermatol</i>. 2004;150(3):598-600. doi:10.1111/j.1365-2133.2003.05807.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/15030353/pubmed" id="15030353" target="_blank">15030353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23541274">
<a name="23541274"></a>Bagg A, Dunphy CH. Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders. <i>Semin Diagn Pathol</i>. 2013;30(2):102-112. doi:10.1053/j.semdp.2012.08.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23541274/pubmed" id="23541274" target="_blank">23541274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28152659">
<a name="28152659"></a>Balci MA, Pamuk GE, Unlu E, Usta U, Pamuk ON. Development of primary central nervous system lymphoma in a systemic lupus erythematosus patient after treatment with mycophenolate mofetil and review of the literature. <i>Lupus</i>. 2017;26(11):1224-1227. doi:10.1177/0961203317691370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28152659/pubmed" id="28152659" target="_blank">28152659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33404096">
<a name="33404096"></a>Bardazzi F, Gallo G, Loi C, Misciali C, Patrizi A, Filippini A. Refractory palmo-plantar discoid lupus erythematosus successfully treated with mycophenolate mofetil: unusual localization and literature review. <i>Dermatol Ther</i>. 2021;34(2):e14743. doi:10.1111/dth.14743<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/33404096/pubmed" id="33404096" target="_blank">33404096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19727839">
<a name="19727839"></a>Baskin E, Ozen S, Cakar N, et al. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis. <i>Pediatr Nephrol</i>. 2010;25(1):111-117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19727839/pubmed" id="19727839" target="_blank">19727839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33568350">
<a name="33568350"></a>Beattie J, Rizvi H, Fuentes P, et al. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. <i>J Immunother Cancer</i>. 2021;9(2):e001884. doi:10.1136/jitc-2020-001884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/33568350/pubmed" id="33568350" target="_blank">33568350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23871408">
<a name="23871408"></a>Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. <i>Am J Kidney Dis</i>. 2013;62(3):403-441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23871408/pubmed" id="23871408" target="_blank">23871408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11522119">
<a name="11522119"></a>Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. <i>Drug Saf</i>. 2001;24(9):645-663. doi:10.2165/00002018-200124090-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11522119/pubmed" id="11522119" target="_blank">11522119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20410913">
<a name="20410913"></a>Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. <i>J Invest Dermatol</i>. 2010;130(8):2041-2048. doi:10.1038/jid.2010.91<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20410913/pubmed" id="20410913" target="_blank">20410913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18087004">
<a name="18087004"></a>Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. <i>Arch Dermatol</i>. 2007;143(12):1536-1542. doi:10.1001/archderm.143.12.1536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18087004/pubmed" id="18087004" target="_blank">18087004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33711005">
<a name="33711005"></a>Bergan S, Brunet M, Hesselink DA, et al. Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Ther Drug Monit.</i> 2021;43(2):150-200. doi:10.1097/FTD.0000000000000871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/33711005/pubmed" id="33711005" target="_blank">33711005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31727565">
<a name="31727565"></a>Bermas BL. Paternal safety of anti-rheumatic medications. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2020;64:77‐84. doi:10.1016/j.bpobgyn.2019.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31727565/pubmed" id="31727565" target="_blank">31727565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25609339">
<a name="25609339"></a>Berti A, Scotti R, Rizzo N, Sabbadini MG, Tresoldi M. Kaposi's sarcoma in a patient with eosinophilic granulomatosis with polyangiitis while taking mycophenolate mofetil. <i>J Allergy Clin Immunol Pract</i>. 2015;3(3):431-432. doi:10.1016/j.jaip.2014.11.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25609339/pubmed" id="25609339" target="_blank">25609339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17504841">
<a name="17504841"></a>Bertsias G, Ioannidis JP, Boletis J, et al. EULAR Recommendations for the Management of Systemic Lupus Erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. <i>Ann Rheum Dis.</i> 2008;67(2):195-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17504841/pubmed" id="17504841" target="_blank">17504841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bird.1">
<a name="Bird.1"></a>Bird SJ. Chronic immunotherapy for myasthenia gravis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20438577">
<a name="20438577"></a>Boddana P, Webb LH, Unsworth J, Brealey M, Bingham C, Harper SJ. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon? <i>Clin Transplant</i> 2011;25:417-419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20438577/pubmed" id="20438577" target="_blank">20438577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25170121">
<a name="25170121"></a>Bolaños-Meade J, Logan BR, Alousi AM, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i>. 2014;124(22):3221-3227. doi:10.1182/blood-2014-06-577023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25170121/pubmed" id="25170121" target="_blank">25170121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35766904">
<a name="35766904"></a>Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). <i>J Eur Acad Dermatol Venereol</i>. 2022;36(10):1689-1704. doi:10.1111/jdv.18220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/35766904/pubmed" id="35766904" target="_blank">35766904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14974945">
<a name="14974945"></a>Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. <i>Am J Transplant</i>. 2004a;4(2):237-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/14974945/pubmed" id="14974945" target="_blank">14974945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20795786">
<a name="20795786"></a>Budde K, Dürr M, Liefeldt L, Neumayer HH, Glander P. Enteric-coated mycophenolate sodium. <i>Expert Opin Drug Saf</i>. 2010;9(6):981-994.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20795786/pubmed" id="20795786" target="_blank">20795786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15041401">
<a name="15041401"></a>Budde K, Glander P, Diekmann F, et al. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. <i>Transplant Proc</i>. 2004b;36(2)(suppl):524S-527S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/15041401/pubmed" id="15041401" target="_blank">15041401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8799515">
<a name="8799515"></a>Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. <i>Br J Clin Pharmacol</i>. 1996;41(6):513-516.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/8799515/pubmed" id="8799515" target="_blank">8799515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9646007">
<a name="9646007"></a>Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. <i>Clin Pharmacokinet</i>. 1998;34(6):429-455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/9646007/pubmed" id="9646007" target="_blank">9646007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25196230">
<a name="25196230"></a>Bunnapradist S, Sampaio MS, Wilkinson AH, et al. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. <i>Am J Nephrol</i>. 2014;40(2):184-190. doi:10.1159/000365360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25196230/pubmed" id="25196230" target="_blank">25196230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17049061">
<a name="17049061"></a>Caillard S, Lelong C, Pessione F, Moulin B; French PTLD Working Group. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. <i>Am J Transplant</i>. 2006;6(11):2735-2742. doi:10.1111/j.1600-6143.2006.01540.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17049061/pubmed" id="17049061" target="_blank">17049061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26126799">
<a name="26126799"></a>Calmet FH, Yarur AJ, Pukazhendhi G, Ahmad J, Bhamidimarri KR. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. <i>Ann Gastroenterol</i>. 2015;28(3):366-373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/26126799/pubmed" id="26126799" target="_blank">26126799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16647514">
<a name="16647514"></a>Cantisani GP, Zanotelli ML, Gleisner AL, de Mello Brandão A, Marroni CA. Enteric-coated mycophenolate sodium experience in liver transplant patients. <i>Transplant Proc</i>. 2006;38(3):932-933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16647514/pubmed" id="16647514" target="_blank">16647514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33564419">
<a name="33564419"></a>Caravaca-Fontán F, Shabaka A, Sánchez-Álamo B, et al; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Recurrent acute interstitial nephritis: what lies beneath. <i>Clin Kidney J</i>. 2020;14(1):197-204. doi:10.1093/ckj/sfaa018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/33564419/pubmed" id="33564419" target="_blank">33564419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.1">
<a name="Cattran.1"></a>Cattran DC, Appel GB. Focal segmental glomerulosclerosis: treatment of primary focal segmental glomerulosclerosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.2">
<a name="Cattran.2"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CellCept.1">
<a name="CellCept.1"></a>CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CellCept.2">
<a name="CellCept.2"></a>CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CellCept.3">
<a name="CellCept.3"></a>CellCept (mycophenolate mofetil) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche Ltd; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CellCept.4">
<a name="CellCept.4"></a>CellCept i.v. (mycophenolate mofetil as hydrochloride) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche Ltd; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CellCept.5">
<a name="CellCept.5"></a>CellCept i.v. (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17583373">
<a name="17583373"></a>Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. <i>J Am Acad Dermatol</i>. 2007;57(4):622-628. doi:10.1016/j.jaad.2007.05.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17583373/pubmed" id="17583373" target="_blank">17583373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20164816">
<a name="20164816"></a>Chapman JR. The KDIGO clinical practice guidelines for the care of kidney transplant recipients. <i>Transplantation</i>. 2010;89(6):644-645.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20164816/pubmed" id="20164816" target="_blank">20164816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27692137">
<a name="27692137"></a>Chartrand S, Swigris JJ, Stanchev L, Lee JS, Brown KK, Fischer A. Clinical features and natural history of interstitial pneumonia with autoimmune features: a single center experience. <i>Respir Med</i>. 2016;119:150-154. doi:10.1016/j.rmed.2016.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/27692137/pubmed" id="27692137" target="_blank">27692137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11148242">
<a name="11148242"></a>Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate Mofetil: A Safe and Promising Immunosuppressant in Neuromuscular Diseases. <i>Neurology</i>. 2001;56(1):94-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11148242/pubmed" id="11148242" target="_blank">11148242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15267008">
<a name="15267008"></a>Chen KJ, Chen CH, Cheng CH, Wu MJ, Shu KH. Risk factors for peptic ulcer disease in renal transplant patients--11 years of experience from a single center. <i>Clin Nephrol</i>. 2004;62(1):14-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/15267008/pubmed" id="15267008" target="_blank">15267008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11477179">
<a name="11477179"></a>Cherney DZ, Zaltzman JS. Mycophenolate mofetil causing deep venous thrombosis in a renal transplant patient with factor V Leiden. <i>Nephrol Dial Transplant</i>. 2001;16(8):1702-1704. doi:10.1093/ndt/16.8.1702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11477179/pubmed" id="11477179" target="_blank">11477179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31656561">
<a name="31656561"></a>Cheung V, Gupta T, Payne M, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary centre. <i>Frontline Gastroenterol</i>. 2019;10(4):364-371. doi:10.1136/flgastro-2018-101146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31656561/pubmed" id="31656561" target="_blank">31656561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235894">
<a name="34235894"></a>Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Rheumatol</i>. 2021;73(8):1366-1383. doi:10.1002/art.41773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/34235894/pubmed" id="34235894" target="_blank">34235894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clarke.1">
<a name="Clarke.1"></a>Clarke J. Management of refractory discoid lupus and subacute cutaneous lupus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25271063">
<a name="25271063"></a>Constantinescu S, Pai A, Coscia LA, Davison JM, Moritz MJ, Armenti VT. Breast-feeding after transplantation. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2014;28(8):1163‐1173. doi:10.1016/j.bpobgyn.2014.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25271063/pubmed" id="25271063" target="_blank">25271063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999109">
<a name="14999109"></a>Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. <i>N Engl J Med.</i> 2004;350(10):971-980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/14999109/pubmed" id="14999109" target="_blank">14999109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30348175">
<a name="30348175"></a>Cooper JC, Rouster-Stevens K, Wright TB, et al. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. <i>Pediatr Rheumatol Online J</i>. 2018;16(1):65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/30348175/pubmed" id="30348175" target="_blank">30348175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20643330">
<a name="20643330"></a>Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2010;29(8):914-956. doi:10.1016/j.healun.2010.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20643330/pubmed" id="20643330" target="_blank">20643330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17664180">
<a name="17664180"></a>Cramer CH 2nd, Mills M, Valentini RP, et al. Clinical presentation and outcome in a cohort of paediatric patients with membranous lupus nephritis. <i>Nephrol Dial Transplant</i>. 2007;22(12):3495-3500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17664180/pubmed" id="17664180" target="_blank">17664180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18223470">
<a name="18223470"></a>Cussonneau X, Bolon-Larger M, Prunet-Spano C, Bastien O, Boulieu R. Evaluation of MPA and MPAG removal by continuous venovenous hemodiafiltration and continuous venovenous hemofiltration.<i> Ther Drug Monit</i>. 2008;30(1):100-102. doi:10.1097/FTD.0b013e3181633667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18223470/pubmed" id="18223470" target="_blank">18223470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15110637">
<a name="15110637"></a>Danesi R, Del Tacca M. Hematologic toxicity of immunosuppressive treatment. <i>Transplant Proc</i>. 2004;36(3):703-704. doi:10.1016/j.transproceed.2004.03.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/15110637/pubmed" id="15110637" target="_blank">15110637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20042178">
<a name="20042178"></a>Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. <i>Am J Ophthalmol</i>. 2010;149(3):423-432.e1-2. doi:10.1016/j.ajo.2009.09.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20042178/pubmed" id="20042178" target="_blank">20042178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25142167">
<a name="25142167"></a>de Andrade LG, Rodrigues MA, Romeiro FG, Garcia PD, Contti MM, de Carvalho MF. Clinicopathologic features and outcome of mycophenolate-induced colitis in renal transplant recipients. <i>Clin Transplant</i>. 2014;28(11):1244-1248. doi:10.1111/ctr.12452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25142167/pubmed" id="25142167" target="_blank">25142167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Denton.1">
<a name="Denton.1"></a>Denton CP. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19846575">
<a name="19846575"></a>Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. <i>Rheumatology.</i> 2009;48(12):1595-1599. doi:10.1093/rheumatology/kep295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19846575/pubmed" id="19846575" target="_blank">19846575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28903965">
<a name="28903965"></a>Deuter CME, Engelmann K, Heiligenhaus A, et al; MYCUV-IIT02 Study Group. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. <i>Br J Ophthalmol</i>. 2018;102(5):647-653. doi:10.1136/bjophthalmol-2017-310156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28903965/pubmed" id="28903965" target="_blank">28903965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diamond.1">
<a name="Diamond.1"></a>Diamond JM, Kotloff RM. Maintenance immunosuppression following lung transplantation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19754409">
<a name="19754409"></a>Díaz-Llopis M, Gallego-Pinazo R, García-Delpech S, Salom-Alonso D. General principles for the treatment of non-infectious uveitis. <i>Inflamm Allergy Drug Targets</i>. 2009;8(4):260-265. doi:10.2174/187152809789352203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19754409/pubmed" id="19754409" target="_blank">19754409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29310963">
<a name="29310963"></a>Dick AD, Rosenbaum JT, Al-Dhibi HA, et al; Fundamentals of Care for Uveitis International Consensus Group. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. <i>Ophthalmology</i>. 2018;125(5):757-773. doi:10.1016/j.ophtha.2017.11.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/29310963/pubmed" id="29310963" target="_blank">29310963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22087680">
<a name="22087680"></a>Dooley MA, Jayne D, Ginzler EM, et al; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. <i>N Engl J Med.</i> 2011;365(20):1886-1895.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/22087680/pubmed" id="22087680" target="_blank">22087680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19573090">
<a name="19573090"></a>Doria C, Ramirez CB, Frank AM, et al. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil. <i>Clin Transplant</i>. 2009;23(6):882-886. doi:10.1111/j.1399-0012.2009.01019.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19573090/pubmed" id="19573090" target="_blank">19573090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12091650">
<a name="12091650"></a>EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. <i>Nephrol Dial Transplant</i>. 2002;(17)(suppl 4):50‐55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12091650/pubmed" id="12091650" target="_blank">12091650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9458011">
<a name="9458011"></a>Eckhoff DE, McGuire BM, Frenette LR, Contrera JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. <i>Transplantation</i>. 1998;65(2):180-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/9458011/pubmed" id="9458011" target="_blank">9458011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415388">
<a name="16415388"></a>Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. <i>Arch Dermatol</i>. 2006;142(1):65-69. doi:10.1001/archderm.142.1.65<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16415388/pubmed" id="16415388" target="_blank">16415388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28197482">
<a name="28197482"></a>Einollahi B, Dolatimehr F. Acute pancreatitis induced by mycophenolate mofetil in a kidney transplant patient. <i>J Nephropharmacol</i>. 2015;4(2):72-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28197482/pubmed" id="28197482" target="_blank">28197482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15896747">
<a name="15896747"></a>Eisen HJ, Kobashigawa J, Keogh A, et al; Mycophenolate Mofetil Cardiac Study Investigators. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. <i>J Heart Lung Transplant</i>. 2005;24(5):517-525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/15896747/pubmed" id="15896747" target="_blank">15896747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23433101">
<a name="23433101"></a>Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. <i>Am J Transplant</i>. 2013;13(5):1203-1216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23433101/pubmed" id="23433101" target="_blank">23433101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17640860">
<a name="17640860"></a>Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. <i>Haematologica</i>. 2007;92(8):1029-1036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17640860/pubmed" id="17640860" target="_blank">17640860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10532541">
<a name="10532541"></a>Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. <i>Transplantation</i>. 1999;68(7):997-1003. doi:10.1097/00007890-199910150-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/10532541/pubmed" id="10532541" target="_blank">10532541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ettenger.1">
<a name="Ettenger.1"></a>Ettenger R, Warshaw B, Menster M, et al. Mycophenolate Mofetil (MMF) in Pediatric (Ped) Renal Transplantation (Tx): A Report of the Ped MMF Study Group (PMMSG). 1996:97 [abstract 97 from ASTP Annual Meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10459543">
<a name="10459543"></a>European Mycophenolate Mofetil Cooperative (EMMC) Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. <i>Transplantation</i>. 1999;68(3):391-396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/10459543/pubmed" id="10459543" target="_blank">10459543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Falk.2">
<a name="Falk.2"></a>Falk RJ, Dall'Era M, Appel GB. Treatment and prognosis of diffuse of focal proliferative lupus nephritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 17, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Falk.1">
<a name="Falk.1"></a>Falk RJ, Kshirsagar AV. Treatment of acute interstitial nephritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 28, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32220834">
<a name="32220834"></a>Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Ann Rheum Dis</i>. 2020;79(6):713-723. doi:10.1136/annrheumdis-2020-216924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/32220834/pubmed" id="32220834" target="_blank">32220834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23457378">
<a name="23457378"></a>Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. <i>J Rheumatol</i>. 2013;40(5):640-646. doi:10.3899/jrheum.121043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23457378/pubmed" id="23457378" target="_blank">23457378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flaherty.1">
<a name="Flaherty.1"></a>Flaherty KR. Treatment and prognosis of nonspecific interstitial pneumonia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16314782">
<a name="16314782"></a>Funch DP, Ko HH, Travasso J, et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. <i>Transplantation</i>. 2005;80(9):1174-1180. doi:10.1097/01.tp.0000169035.10572.c6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16314782/pubmed" id="16314782" target="_blank">16314782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19377515">
<a name="19377515"></a>Furlong T, Martin P, Flowers ME, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. <i>Bone Marrow Transplant</i>. 2009;44(11):739-748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19377515/pubmed" id="19377515" target="_blank">19377515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565799">
<a name="14565799"></a>Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. <i>Ann Pharmacother</i>. 2003;37(11):1685-1693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/14565799/pubmed" id="14565799" target="_blank">14565799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18579209">
<a name="18579209"></a>Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. <i>Ophthalmology</i>. 2008;115(10):1826-1832. doi:10.1016/j.ophtha.2008.04.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18579209/pubmed" id="18579209" target="_blank">18579209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21641078">
<a name="21641078"></a>Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. <i>J Am Acad Dermatol</i>. 2011;65(4):717-721. doi:10.1016/j.jaad.2010.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21641078/pubmed" id="21641078" target="_blank">21641078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11127313">
<a name="11127313"></a>Geetha D, Zachary JB, Baldado HM, Kronz JD, Kraus ES. Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. <i>Clin Transplant</i>. 2000;14(6):586-591. doi:10.1034/j.1399-0012.2000.140612.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11127313/pubmed" id="11127313" target="_blank">11127313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18071023">
<a name="18071023"></a>Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. <i>CHEST.</i> 2008;133:455-460. doi:10.1378/chest.06-2861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18071023/pubmed" id="18071023" target="_blank">18071023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33121819">
<a name="33121819"></a>Gierczak V, Jouve T, Malvezzi P, et al. Impact of immunosuppressive strategies on post-kidney transplantation thrombocytopenia. <i>Transplant Proc</i>. 2021;53(3):941-949. doi:10.1016/j.transproceed.2020.09.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/33121819/pubmed" id="33121819" target="_blank">33121819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33132635">
<a name="33132635"></a>Gioco R, Corona D, Ekser B, et al. Gastrointestinal complications after kidney transplantation. <i>World J Gastroenterol</i>. 2020;26(38):5797-5811. doi:10.3748/wjg.v26.i38.5797<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/33132635/pubmed" id="33132635" target="_blank">33132635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19651590">
<a name="19651590"></a>Gipson DS, Massengill SF, Yao L, et al. Management of Childhood Onset Nephrotic Syndrome. <i>Pediatrics</i>. 2009;124(2):747-757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19651590/pubmed" id="19651590" target="_blank">19651590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21734640">
<a name="21734640"></a>Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. <i>Kidney Int</i>. 2011;80(8):868-878. doi:10.1038/ki.2011.195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21734640/pubmed" id="21734640" target="_blank">21734640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25049068">
<a name="25049068"></a>Glanville AR, Aboyoun C, Klepetko W, et al. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation. <i>J Heart Lung Transplant</i>. 2015;34(1):16-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25049068/pubmed" id="25049068" target="_blank">25049068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29096935">
<a name="29096935"></a>Goel R, Danda D, Joseph G, et al. Long-term outcome of 251 patients with Takayasu arteritis on combination immunosuppressant therapy: single centre experience from a large tertiary care teaching hospital in Southern India. <i>Semin Arthritis Rheum</i>. 2018;47(5):718-726. doi:10.1016/j.semarthrit.2017.09.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/29096935/pubmed" id="29096935" target="_blank">29096935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20054700">
<a name="20054700"></a>Goel R, Danda D, Mathew J, Edwin N. Mycophenolate mofetil in Takayasu's arteritis. <i>Clin Rheumatol</i>. 2010;29(3):329-332. doi:10.1007/s10067-009-1333-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20054700/pubmed" id="20054700" target="_blank">20054700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35718887">
<a name="35718887"></a>Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(9):1399-1408. doi:10.1002/acr.24893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/35718887/pubmed" id="35718887" target="_blank">35718887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23464993">
<a name="23464993"></a>Green M. Introduction: Infections in solid organ transplantation. <i>Am J Transplant</i>. 2013;13(suppl 4):3-8. doi:10.1111/ajt.12093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23464993/pubmed" id="23464993" target="_blank">23464993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19295318">
<a name="19295318"></a>Groetzner J, Kaczmarek I, Schulz U, et al; VENINAHTx Investigators. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. <i>Transplantation</i>. 2009;87(5):726-733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19295318/pubmed" id="19295318" target="_blank">19295318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23423270">
<a name="23423270"></a>Guethoff S, Meiser BM, Groetzner J, et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. <i>Transplantation</i>. 2013;95(4):629-634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23423270/pubmed" id="23423270" target="_blank">23423270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22556106">
<a name="22556106"></a>Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. <i>Arthritis Care Res (Hoboken).</i> 2012;64(6):797-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/22556106/pubmed" id="22556106" target="_blank">22556106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12472362">
<a name="12472362"></a>Hanjani NM, Nousari CH. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. <i>Arch Dermatol</i>. 2002;138(12):1616-1618. doi:10.1001/archderm.138.12.1616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12472362/pubmed" id="12472362" target="_blank">12472362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18668650">
<a name="18668650"></a>Hao C, Anwei M, Bing C, et al. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. <i>Liver Transpl</i>. 2008;14(8):1165-1173. doi:10.1002/lt.21600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18668650/pubmed" id="18668650" target="_blank">18668650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hardinger.1">
<a name="Hardinger.1"></a>Hardinger K, Brennen DC. Kidney transplantation in adult: maintenance immunosuppressive therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18394000">
<a name="18394000"></a>Hardinger KL, Hebbar S, Bloomer T, Murillo D. Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil. <i>Clin Transplant</i>. 2008;22(5):555-561. doi:10.1111/j.1399-0012.2008.00820.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18394000/pubmed" id="18394000" target="_blank">18394000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12078944">
<a name="12078944"></a>Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. <i>Clin Nephrol</i>. 2002;57(6):421-424. doi:10.5414/cnp57421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12078944/pubmed" id="12078944" target="_blank">12078944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16344316">
<a name="16344316"></a>Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. <i>J Clin Oncol</i>. 2006;24(3):444-453. doi:10.1200/JCO.2005.03.1765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16344316/pubmed" id="16344316" target="_blank">16344316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20405499">
<a name="20405499"></a>Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. <i>Muscle Nerve</i>. 2010;41(5):593-598. doi:10.1002/mus.21640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20405499/pubmed" id="20405499" target="_blank">20405499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31270110">
<a name="31270110"></a>Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Ann Rheum Dis</i>. 2020;79(1):19-30. doi:10.1136/annrheumdis-2019-215672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31270110/pubmed" id="31270110" target="_blank">31270110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23182601">
<a name="23182601"></a>Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. <i>Am J Kidney Dis</i>. 2013;61(1):74-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23182601/pubmed" id="23182601" target="_blank">23182601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23307324">
<a name="23307324"></a>Henes JC, Horger M, Amberger C, et al. Enteric-coated mycophenolate sodium for progressive systemic sclerosis—a prospective open-label study with CT histography for monitoring of pulmonary fibrosis. <i>Clin Rheumatol.</i> 2013;32(5):673-678. doi:10.1007/s10067-012-2155-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23307324/pubmed" id="23307324" target="_blank">23307324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28188239">
<a name="28188239"></a>Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Ann Rheum Dis. </i>2017;76:1207-1218. doi:10.1136/annrheumdis-2016-210503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28188239/pubmed" id="28188239" target="_blank">28188239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hertl.1">
<a name="Hertl.1"></a>Hertl M, Geller S. Initial management of pemphigus vulgaris and pemphigus foliaceus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060104">
<a name="21060104"></a>Hiemstra TF, Walsh M, Mahr A, et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. <i>JAMA</i>. 2010;304(21):2381-2388. doi:10.1001/jama.2010.1658<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21060104/pubmed" id="21060104" target="_blank">21060104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16539644">
<a name="16539644"></a>Hochegger K, Gruber J, Lhotta K. Acute inflammatory syndrome induced by mycophenolate mofetil in a patient following kidney transplantation. <i>Am J Transplant</i>. 2006;6(4):852-854. doi:10.1111/j.1600-6143.2006.01251.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16539644/pubmed" id="16539644" target="_blank">16539644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16441367">
<a name="16441367"></a>Hodo Y, Tsuji K, Mizukoshi E, et al. Pure red cell aplasia associated with concomitant use of mycophenolate mofetil and ribavirin in post-transplant recurrent hepatitis C. <i>Transpl Int</i>. 2006;19(2):170-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16441367/pubmed" id="16441367" target="_blank">16441367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11859257">
<a name="11859257"></a>Hörl MP, Schmitz M, Ivens K, Grabensee B. Opportunistic infections after renal transplantation. <i>Curr Opin Urol</i>. 2002;12(2):115-123. doi:10.1097/00042307-200203000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11859257/pubmed" id="11859257" target="_blank">11859257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36745456">
<a name="36745456"></a>Hou FF, Xie D, Wang J, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. <i>JAMA Netw Open</i>. 2023;6(2):e2254054. doi:10.1001/jamanetworkopen.2022.54054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/36745456/pubmed" id="36745456" target="_blank">36745456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20833738">
<a name="20833738"></a>Houssiau FA, D'Cruz D, Sangle S, et al; MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. <i>Ann Rheum Dis</i>. 2010;69(12):2083-2089. doi:10.1136/ard.2010.131995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20833738/pubmed" id="20833738" target="_blank">20833738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17302587">
<a name="17302587"></a>Hummel M, Yonan N, Ross H, et al; ERL 2401 Study Group. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. <i>Clin Transplant</i>. 2007;21(1):18-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17302587/pubmed" id="17302587" target="_blank">17302587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12060875">
<a name="12060875"></a>Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. <i>Clin Infect Dis</i>. 2002;35(1):53-61. doi:10.1086/340867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12060875/pubmed" id="12060875" target="_blank">12060875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17509945">
<a name="17509945"></a>Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. <i>Clin Gastroenterol Hepatol</i>. 2007;5(7):799-802. doi:10.1016/j.cgh.2007.02.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17509945/pubmed" id="17509945" target="_blank">17509945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17538999">
<a name="17538999"></a>Jain A, Venkataramanan R, Kwong T, et al. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. <i>Liver Transpl</i>. 2007;13(6):791-796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17538999/pubmed" id="17538999" target="_blank">17538999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9630824">
<a name="9630824"></a>Johnson HJ, Swan SK, Heim-Duthoy KL, Nicholls AJ, Tsina I, Tarnowski T. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. <i>Clin Pharmacol Ther.</i> 1998;63(5):512-518. doi:10.1016/S0009-9236(98)90102-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/9630824/pubmed" id="9630824" target="_blank">9630824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17164710">
<a name="17164710"></a>Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. <i>Transplantation</i>. 2006;82(11):1413-1418. doi:10.1097/01.tp.0000242137.68863.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17164710/pubmed" id="17164710" target="_blank">17164710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31410987">
<a name="31410987"></a>Jones BP, Saso S, Bracewell-Milnes T, et al. Human uterine transplantation: a review of outcomes from the first 45 cases. <i>BJOG</i>. 2019;126(11):1310‐1319. doi:10.1111/1471-0528.15863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31410987/pubmed" id="31410987" target="_blank">31410987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32567256">
<a name="32567256"></a>Jung HY, Lee S, Jeon Y, et al. Mycophenolic acid trough concentration and dose are associated with hematologic abnormalities but not rejection in kidney transplant recipients. <i>J Korean Med Sci</i>. 2020;35(24):e185. doi:10.3346/jkms.2020.35.e185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/32567256/pubmed" id="32567256" target="_blank">32567256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31293110">
<a name="31293110"></a>Jung UH, Kwak SG, Choe JY, Lee SS, Kim SK. The effect of mycophenolate mofetil on non-renal manifestations in systemic lupus erythematosus: results from Korean Lupus Network Registry. <i>J Korean Med Sci</i>. 2019;34(27):e185. doi:10.3346/jkms.2019.34.e185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31293110/pubmed" id="31293110" target="_blank">31293110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23415313">
<a name="23415313"></a>Kaczmarek I, Zaruba MM, Beiras-Fernandez A, et al. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results. <i>J Heart Lung Transplant</i>. 2013;32(3):277-284. doi:10.1016/j.healun.2012.11.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23415313/pubmed" id="23415313" target="_blank">23415313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14963204">
<a name="14963204"></a>Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate mofetil. <i>Rheumatology (Oxford)</i>. 2004;43(3):377-380. doi:10.1093/rheumatology/keh012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/14963204/pubmed" id="14963204" target="_blank">14963204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29923335">
<a name="29923335"></a>Karagun BS, Akbas T, Arpaci T, Antmen B. Cecum perforation induced by mycophenolate mofetil after hematopoietic stem cell transplantation: A case report and review of literature. <i>Pediatr Transplant</i>. 2018;e13223. doi:10.1111/petr.13223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/29923335/pubmed" id="29923335" target="_blank">29923335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14987202">
<a name="14987202"></a>Keven K, Sahin M, Kutlay S, et al. Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and azathioprine. <i>Transpl Infect Dis</i>. 2003;5:181-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/14987202/pubmed" id="14987202" target="_blank">14987202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31332670">
<a name="31332670"></a>Kiang TK, Ensom MH. Exposure-toxicity relationships of mycophenolic acid in adult kidney transplant patients. <i>Clin Pharmacokinet</i>. 2019;58(12):1533-1552. doi:10.1007/s40262-019-00802-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31332670/pubmed" id="31332670" target="_blank">31332670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30178220">
<a name="30178220"></a>Kiang TK, Partovi N, Shapiro RJ, Berman JM, Collier AC, Ensom MH. Regression and genomic analyses on the association between dose-normalized mycophenolic acid exposure and absolute neutrophil count in steroid-free, de novo kidney transplant recipients. <i>Clin Drug Investig</i>. 2018;38(11):1011-1022. doi:10.1007/s40261-018-0694-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/30178220/pubmed" id="30178220" target="_blank">30178220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34556256">
<a name="34556256"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. <i>Kidney Int</i>. 2021b;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/34556256/pubmed" id="34556256" target="_blank">34556256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. <i>Kidney Int Suppl</i>. 2021;100(suppl 4):S1–S276. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf. Accessed October 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19845597">
<a name="19845597"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>Am J Transplant</i>. 2009;9(suppl 3):S1-S155. doi:10.1111/j.1600-6143.2009.02834.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19845597/pubmed" id="19845597" target="_blank">19845597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-King.1">
<a name="King.1"></a>King TE. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8061021">
<a name="8061021"></a>Kirklin JK, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. <i>J Heart Lung Transplant</i>. 1994;13(3):444-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/8061021/pubmed" id="8061021" target="_blank">8061021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19157948">
<a name="19157948"></a>Kluger N, Poirier P, Guilpain P, Baixench MT, Cohen P, Paugam A. Cryptococcal meningitis in a patient treated with infliximab and mycophenolate mofetil for Behcet's disease. <i>Int J Infect Dis</i>. 2009;13(5):e325. doi:10.1016/j.ijid.2008.11.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19157948/pubmed" id="19157948" target="_blank">19157948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16890114">
<a name="16890114"></a>Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. <i>J Heart Lung Transplant</i>. 2006;25(8):935-941.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16890114/pubmed" id="16890114" target="_blank">16890114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18438909">
<a name="18438909"></a>Konon I, Cronin ME, Ryan LM. Acute inflammatory syndrome following introduction of mycophenolate mofetil in a patient with systemic lupus erythematosus. <i>Arthritis Rheum</i>. 2008;59(5):754-756. doi:10.1002/art.23574<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18438909/pubmed" id="18438909" target="_blank">18438909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16286784">
<a name="16286784"></a>Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. <i>Nephron Clin Pract</i>. 2006;102(3-4):c100-107. doi:10.1159/000089667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16286784/pubmed" id="16286784" target="_blank">16286784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17408395">
<a name="17408395"></a>Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. <i>Br J Dermatol</i>. 2007;156(6):1321-1327. doi:10.1111/j.1365-2133.2007.07826.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17408395/pubmed" id="17408395" target="_blank">17408395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272259">
<a name="29272259"></a>Kurnicka K, Ciszek M, Lichodziejewska B, Zdończyk O, Pruszczyk P. Fatal course of perivalvular extension of infective endocarditis in a patient after aortic valve replacement treated with immunosuppressive drugs. <i>Pol Arch Intern Med</i>. 2017;127(12):882-884. doi:10.20452/pamw.4173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/29272259/pubmed" id="29272259" target="_blank">29272259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20056756">
<a name="20056756"></a>Kuypers DR, Le Meur Y, Cantarovich M, et al; Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. <i>Clin J Am Soc Nephrol.</i> 2010;5(2):341-358. doi:10.2215/CJN.07111009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20056756/pubmed" id="20056756" target="_blank">20056756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lake.1">
<a name="Lake.1"></a>Lake FR. Interstitial lung disease in rheumatoid arthritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12962866">
<a name="12962866"></a>Lama R, Santos F, Algar FJ, Alvarez A, Baamonde C. Lung transplants with tacrolimus and mycophenolate mofetil: a review. <i>Transplant Proc</i>. 2003;35(5):1968-1973.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12962866/pubmed" id="12962866" target="_blank">12962866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15077273">
<a name="15077273"></a>Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. <i>Arthritis Rheum</i>. 2004;51(2):278-283. doi:10.1002/art.20240<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/15077273/pubmed" id="15077273" target="_blank">15077273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21245794">
<a name="21245794"></a>Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. <i>Transplantation</i>. 2011;91(4):470-478. doi:10.1097/TP.0b013e318205568c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21245794/pubmed" id="21245794" target="_blank">21245794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21378404">
<a name="21378404"></a>Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. <i>Ann Rheum Dis.</i> 2011;70(6):1104-1107. doi:10.1136/ard.2010.142000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21378404/pubmed" id="21378404" target="_blank">21378404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31467148">
<a name="31467148"></a>Lee A, Bridges LR, Lloyd M, Barker R, Wren DR, Galtrey CM. Epstein-Barr virus associated CNS lymphoproliferative disorder after long-term immunosuppression. <i>Pract Neurol</i>. 2020;20(1):83-86. doi:10.1136/practneurol-2019-002356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31467148/pubmed" id="31467148" target="_blank">31467148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18555088">
<a name="18555088"></a>Lehmkuhl H, Hummel M, Kobashigawa J, et al. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil. <i>Transplant Proc</i>. 2008;40(4):953-955. doi:10.1016/j.transproceed.2008.03.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18555088/pubmed" id="18555088" target="_blank">18555088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27924855">
<a name="27924855"></a>Li J, Yang Y, Zhao J, Li M, Tian X, Zeng X. The efficacy of mycophenolate mofetil for the treatment of Chinese Takayasu's arteritis. <i>Sci Rep</i>. 2016;6:38687. doi:10.1038/srep38687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/27924855/pubmed" id="27924855" target="_blank">27924855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32583620">
<a name="32583620"></a>Lima B, Gibson GT, Vullaganti S, et al. COVID-19 in recent heart transplant recipients: Clinicopathologic features and early outcomes. <i>Transpl Infect Dis</i>. 2020;22(5):e13382. doi:10.1111/tid.13382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/32583620/pubmed" id="32583620" target="_blank">32583620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8918281">
<a name="8918281"></a>Lipsky JJ. Mycophenolate mofetil. <i>Lancet.</i> 1996;348(9038):1357-1359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/8918281/pubmed" id="8918281" target="_blank">8918281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25420815">
<a name="25420815"></a>López LF, Martínez CJ, Castañeda DA, Hernández AC, Pérez HC, Lozano E. Pregnancy and kidney transplantation, triple hazard? Current concepts and algorithm for approach of preconception and perinatal care of the patient with kidney transplantation. <i>Transplant Proc</i>. 2014;46(9):3027‐3031. doi:10.1016/j.transproceed.2014.07.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25420815/pubmed" id="25420815" target="_blank">25420815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24754682">
<a name="24754682"></a>Lopez-Solis R, DeVera M, Steel J, et al. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil. <i>Clin Transplant</i>. 2014;28(7):783-788. doi:10.1111/ctr.12379<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/24754682/pubmed" id="24754682" target="_blank">24754682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23281277">
<a name="23281277"></a>Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. <i>Liver Transpl</i>. 2013;19(1):3‐26. doi:10.1002/lt.23566<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23281277/pubmed" id="23281277" target="_blank">23281277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29707591">
<a name="29707591"></a>Macauley P, Rapp M, Park S, et al. Miliary tuberculosis presenting with meningitis in a patient treated with mycophenolate for lupus nephritis: challenges in diagnosis and review of the literature. <i>J Investig Med High Impact Case Rep</i>. 2018;6:2324709618770226. doi:10.1177/2324709618770226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/29707591/pubmed" id="29707591" target="_blank">29707591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31863477">
<a name="31863477"></a>Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2020;72(2):671-722. doi:10.1002/hep.31065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31863477/pubmed" id="31863477" target="_blank">31863477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10720968">
<a name="10720968"></a>MacPhee IA, Spreafico S, Bewick M, et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. <i>Kidney Int</i>. 2000;57(3):1164-1168. doi:10.1046/j.1523-1755.2000.00943.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/10720968/pubmed" id="10720968" target="_blank">10720968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15572389">
<a name="15572389"></a>Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. <i>Rheumatology (Oxford)</i>. 2005;44(3):386-389. doi:10.1093/rheumatology/keh499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/15572389/pubmed" id="15572389" target="_blank">15572389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16545729">
<a name="16545729"></a>Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. <i>Biol Blood Marrow Transplant</i>. 2006;12(4):454-465. doi:10.1016/j.bbmt.2005.12.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16545729/pubmed" id="16545729" target="_blank">16545729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20222881">
<a name="20222881"></a>Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. <i>Acta Paediatr</i>. 2010;99(7):967-974.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20222881/pubmed" id="20222881" target="_blank">20222881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20694498">
<a name="20694498"></a>Matsui K, Shibagaki Y, Sasaki H, Chikaraishi T, Yasuda T, Kimura K. Mycophenolate mofetil-induced agranulocytosis in a renal transplant recipient. <i>Clin Exp Nephrol</i>. 2010;14(6):637-640. doi:10.1007/s10157-010-0323-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20694498/pubmed" id="20694498" target="_blank">20694498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235884">
<a name="34235884"></a>Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. <i>Arthritis Rheumatol</i>. 2021;73(8):1349-1365. doi:10.1002/art.41774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/34235884/pubmed" id="34235884" target="_blank">34235884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16612275">
<a name="16612275"></a>McNeil K, Glanville AR, Wahlers T, et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. <i>Transplantation</i>. 2006;81(7):998-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16612275/pubmed" id="16612275" target="_blank">16612275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31062373">
<a name="31062373"></a>Meaney CJ, Sudchada P, Consiglio JD, et al. Influence of calcineurin inhibitor and sex on mycophenolic acid pharmacokinetics and adverse effects post-renal transplant. <i>J Clin Pharmacol</i>. 2019;59(10):1351-1365. doi:10.1002/jcph.1428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31062373/pubmed" id="31062373" target="_blank">31062373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26886206">
<a name="26886206"></a>Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German Neurological Society. <i>J Neurol</i>. 2016;263(8):1473-1494. doi:10.1007/s00415-016-8045-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/26886206/pubmed" id="26886206" target="_blank">26886206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22467932">
<a name="22467932"></a>Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. <i>J Rheumatol.</i> 2012;39(6):1241-1247. doi:10.3899/jrheum.111229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/22467932/pubmed" id="22467932" target="_blank">22467932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19493586">
<a name="19493586"></a>Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. <i>J Am Acad Dermatol.</i> 2009;61(3):451-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19493586/pubmed" id="19493586" target="_blank">19493586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14638974">
<a name="14638974"></a>Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. <i>Neurology.</i> 2003;61(10):1438-1440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/14638974/pubmed" id="14638974" target="_blank">14638974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.2">
<a name="Merkel.2"></a>Merkel PA. Treatment of Takayasu arteritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.1">
<a name="Merkel.1"></a>Merkel PA, Kaplan AA, Falk RJ. Granulomatosis with polyangiitis and microscopic polyangiitis: induction and maintenance therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.1">
<a name="Meyrier.1"></a>Meyrier A, Radhikrishnan J. Minimal change disease: treatment in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28346297">
<a name="28346297"></a>Midtvedt K, Bergan S, Reisæter AV, Vikse BE, Åsberg A. Exposure to mycophenolate and fatherhood. <i>Transplantation</i>. 2017;101(7):e214‐e217. doi:10.1097/TP.0000000000001747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28346297/pubmed" id="28346297" target="_blank">28346297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30395075">
<a name="30395075"></a>Mir R, Shaw HM, Nathan PD. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis. <i>Melanoma Res</i>. 2019;29(1):102-106. doi:10.1097/CMR.0000000000000543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/30395075/pubmed" id="30395075" target="_blank">30395075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19705921">
<a name="19705921"></a>Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II. <i>Clin Pharmacokinet</i>. 2009;48(8):489-516.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19705921/pubmed" id="19705921" target="_blank">19705921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10482936">
<a name="10482936"></a>Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. <i>Bone Marrow Transplant</i>. 1999;24(5):517-520. doi:10.1038/sj.bmt.1701936<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/10482936/pubmed" id="10482936" target="_blank">10482936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562232">
<a name="9562232"></a>Morgera S, Neumayer HH, Fritsche L, et al. Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis. <i>Int J Clin Pharmacol Ther</i>. 1998;36(3):159-163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/9562232/pubmed" id="9562232" target="_blank">9562232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30220537">
<a name="30220537"></a>Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence. <i>Semin Arthritis Rheum</i>. 2019;48(5):911‐920. doi:10.1016/j.semarthrit.2018.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/30220537/pubmed" id="30220537" target="_blank">30220537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murrell.1">
<a name="Murrell.1"></a>Murrell DF, Ramirez-Quizon M. Management and prognosis of bullous pemphigoid. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mycophenolicacid.1">
<a name="Mycophenolicacid.1"></a>Mycophenolic acid [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Myfortic.1">
<a name="Myfortic.1"></a>Myfortic (mycophenolate sodium) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Myfortic.2">
<a name="Myfortic.2"></a>Myfortic (mycophenolate sodium) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17700162">
<a name="17700162"></a>Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. <i>Transplantation</i>. 2007;84(3):362-373. doi:10.1097/01.tp.0000276936.14041.6c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17700162/pubmed" id="17700162" target="_blank">17700162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19177449">
<a name="19177449"></a>Nashan B, Saliba F, Durand F, et al. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. <i>Liver Transpl</i>. 2009;15(2):136-147. doi:10.1002/lt.21657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19177449/pubmed" id="19177449" target="_blank">19177449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19034021">
<a name="19034021"></a>Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. <i>Transplantation</i>. 2008;86(10):1474-1478. doi:10.1097/TP.0b013e31818b62c8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19034021/pubmed" id="19034021" target="_blank">19034021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nemecek.1">
<a name="Nemecek.1"></a>Nemecek BD, Hammond DA, eds. <i>Demystifying Drug Dosing in Renal Dysfunction</i>. American Society of Health-System Pharmacists; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19542873">
<a name="19542873"></a>Nguyen T, Park JY, Scudiere JR, Montgomery E. Mycophenolic acid (cellcept and myofortic) induced injury of the upper GI tract. <i>Am J Surg Pathol</i>. 2009;33(9):1355-1363. doi:10.1097/PAS.0b013e3181a755bd<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19542873/pubmed" id="19542873" target="_blank">19542873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12393457">
<a name="12393457"></a>Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. <i>Blood</i>. 2003;101(4):1620-1629. doi:10.1182/blood-2002-05-1340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12393457/pubmed" id="12393457" target="_blank">12393457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16899504">
<a name="16899504"></a>Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis—a retrospective analysis. <i>Rheumatology. </i>2007;46(3):442-445. doi:10.1093/rheumatology/kel244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16899504/pubmed" id="16899504" target="_blank">16899504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25933090">
<a name="25933090"></a>Omair MA, Alahmadi A, Johnson SR. Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. <i>PLoS One</i>. 2015;10(5):e0124205. doi:10.1371/journal.pone.0124205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25933090/pubmed" id="25933090" target="_blank">25933090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16221103">
<a name="16221103"></a>Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. <i>Nephrology (Carlton).</i> 2005;10(5):504-510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16221103/pubmed" id="16221103" target="_blank">16221103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20217287">
<a name="20217287"></a>Onishi C, Ohashi K, Sawada T, et al. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. <i>Int J Hematol</i>. 2010;91(3):464-470. doi:10.1007/s12185-010-0516-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20217287/pubmed" id="20217287" target="_blank">20217287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28450313">
<a name="28450313"></a>Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. <i>Ann Rheum Dis</i>. 2017;76(9):1575-1582. doi:10.1136/annrheumdis-2016-210882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28450313/pubmed" id="28450313" target="_blank">28450313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21760569">
<a name="21760569"></a>Ortega F, Sánchez-Fructuoso A, Cruzado JM, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. <i>Transplantation</i>. 2011;92(4):426-432. doi:10.1097/TP.0b013e31822527ca<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21760569/pubmed" id="21760569" target="_blank">21760569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18727660">
<a name="18727660"></a>Ostronoff F, Ostronoff M, Souto-Maior AP, et al. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. <i>Clin Transplant</i>. 2009;23(1):33-38. doi:10.1111/j.1399-0012.2008.00894.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18727660/pubmed" id="18727660" target="_blank">18727660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18763324">
<a name="18763324"></a>Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. <i>Am J Surg Pathol</i>. 2008;32(9):1367-1372. doi:10.1097/pas.0b013e31816bf3fe<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18763324/pubmed" id="18763324" target="_blank">18763324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32220510">
<a name="32220510"></a>Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: core curriculum 2020. <i>Am J Kidney Dis</i>. 2020;76(2):265-281. doi:10.1053/j.ajkd.2019.10.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/32220510/pubmed" id="32220510" target="_blank">32220510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12194926">
<a name="12194926"></a>Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. <i>Clin Chem</i>. 2002;48(9):1497-1504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12194926/pubmed" id="12194926" target="_blank">12194926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32004485">
<a name="32004485"></a>Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematol</i>. 2020;7(2):e157-e167. doi:10.1016/S2352-3026(19)30256-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/32004485/pubmed" id="32004485" target="_blank">32004485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27639443">
<a name="27639443"></a>Perez-Aytes A, Marin-Reina P, Boso V, Ledo A, Carey JC, Vento M. Mycophenolate mofetil embryopathy: A newly recognized teratogenic syndrome. <i>Eur J Med Genet</i>. 2017;60(1):16-21. doi:10.1016/j.ejmg.2016.09.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/27639443/pubmed" id="27639443" target="_blank">27639443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pham.1">
<a name="Pham.1"></a>Pham MX. Heart transplantation in adults: induction and maintenance of immunosuppressive therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34350491">
<a name="34350491"></a>Philobos M, Perkins A, Karabayas M, et al. A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis. <i>Rheumatol Int</i>. 2021;41(10):1811-1814. doi:10.1007/s00296-021-04961-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/34350491/pubmed" id="34350491" target="_blank">34350491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17699278">
<a name="17699278"></a>Preddie DC, Markowitz GS, Radhakrishnan J, et al. Mycophenolate mofetil for the treatment of interstitial nephritis. <i>Clin J Am Soc Nephrol</i>. 2006;1(4):718-722. doi:10.2215/CJN.01711105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17699278/pubmed" id="17699278" target="_blank">17699278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24917273">
<a name="24917273"></a>Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. <i>Ophthalmology</i>. 2014;121(10):1863-1870. doi:10.1016/j.ophtha.2014.04.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/24917273/pubmed" id="24917273" target="_blank">24917273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31503307">
<a name="31503307"></a>Rathinam SR, Gonzales JA, Thundikandy R, et al; FAST Research Group. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. <i>JAMA</i>. 2019;322(10):936-945. doi:10.1001/jama.2019.12618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31503307/pubmed" id="31503307" target="_blank">31503307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30385039">
<a name="30385039"></a>Rémy P, Audard V, Natella PA, et al; MSN trial investigators. An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). <i>Kidney Int</i>. 2018;94(6):1217-1226. doi:10.1016/j.kint.2018.07.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/30385039/pubmed" id="30385039" target="_blank">30385039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19497072">
<a name="19497072"></a>Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. <i>Transpl Infect Dis</i>. 2009;11(4):290-297. doi:10.1111/j.1399-3062.2009.00407.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19497072/pubmed" id="19497072" target="_blank">19497072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23792500">
<a name="23792500"></a>Roan JN, Chou CH, Hsu CH, et al. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. <i>Ann Transplant</i>. 2013;18:43-52. doi:10.12659/AOT.883812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23792500/pubmed" id="23792500" target="_blank">23792500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29050991">
<a name="29050991"></a>Roberts SK, Lim R, Strasser S, et al; ALA Clinical Research Network. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. <i>Clin Gastroenterol Hepatol</i>. 2018;16(2):268-277. doi:10.1016/j.cgh.2017.09.063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/29050991/pubmed" id="29050991" target="_blank">29050991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19067916">
<a name="19067916"></a>Robertson J, Elidemir O, Saz EU, et al. Hypogammaglobulinemia: incidence, risk factors, and outcomes following pediatric lung transplantation. <i>Pediatr Transplant</i>. 2009;13:754-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19067916/pubmed" id="19067916" target="_blank">19067916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18482049">
<a name="18482049"></a>Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. <i>Clin Transplant</i>. 2008;22(3):281-291. doi:10.1111/j.1399-0012.2007.00783.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/18482049/pubmed" id="18482049" target="_blank">18482049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16436974">
<a name="16436974"></a>Rook M, Postma DS, van der Jagt EJ, et al. Mycophenolate mofetil and bronchiectasis in kidney transplant patients: a possible relationship. <i>Transplantation</i>. 2006;81:287-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16436974/pubmed" id="16436974" target="_blank">16436974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34560137">
<a name="34560137"></a>Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. <i>Kidney Int</i>. 2022;101(2):403-413. doi:10.1016/j.kint.2021.08.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/34560137/pubmed" id="34560137" target="_blank">34560137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16636243">
<a name="16636243"></a>Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? <i>Neurology</i>. 2006;66(8):1245-1247. doi:10.1212/01.wnl.0000208416.32471.c0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16636243/pubmed" id="16636243" target="_blank">16636243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19589481">
<a name="19589481"></a>Sabry W, Le Blanc R, Labbé AC, et al. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. <i>Biol Blood Marrow Transplant.</i> 2009;15(8):919-929.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19589481/pubmed" id="19589481" target="_blank">19589481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28133906">
<a name="28133906"></a>Saliba F, Duvoux C, Gugenheim J, et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial. <i>Am J Transplant</i>. 2017;17(7):1843-1852. doi:10.1111/ajt.14212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28133906/pubmed" id="28133906" target="_blank">28133906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14974944">
<a name="14974944"></a>Salvadori M, Holzer H, de Mattos A, et al; ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. <i>Am J Transplant</i>. 2004;4(2):231-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/14974944/pubmed" id="14974944" target="_blank">14974944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27358333">
<a name="27358333"></a>Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. <i>Neurology</i>. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/27358333/pubmed" id="27358333" target="_blank">27358333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28979773">
<a name="28979773"></a>Sandoval D, Poveda R, Draibe J, et al. Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. <i>Clin Kidney J</i>. 2017;10(5):632-638. doi:10.1093/ckj/sfx035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28979773/pubmed" id="28979773" target="_blank">28979773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12100205">
<a name="12100205"></a>Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. <i>Br J Dermatol</i>. 2002;147(1):174-178. doi:10.1046/j.1365-2133.2002.04875.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12100205/pubmed" id="12100205" target="_blank">12100205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17969182">
<a name="17969182"></a>Schecter JM, Mears JG, Alobeid B, Gaglio PJ. Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus. <i>Liver Transpl</i>. 2007;13(11):1589-1592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17969182/pubmed" id="17969182" target="_blank">17969182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11558484">
<a name="11558484"></a>Schlitt HJ, Barkmann A, Böker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. <i>Lancet</i>. 2001;357(9256):587-591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11558484/pubmed" id="11558484" target="_blank">11558484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21832958">
<a name="21832958"></a>Schmeding M, Kiessling A, Neuhaus R, et al. Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. <i>Transplantation.</i> 2011;92(8):923-929.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21832958/pubmed" id="21832958" target="_blank">21832958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.<i> J Clin Oncol.</i> 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17989103">
<a name="17989103"></a>Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. <i>Nephrol Dial Transplant</i>. 2008;23(6):1926-1930. doi:10.1093/ndt/gfm538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17989103/pubmed" id="17989103" target="_blank">17989103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8588243">
<a name="8588243"></a>Shaw LM, Sollinger HW, Halloran P, et al. Mycophenolate Mofetil: A Report of the Consensus Panel. <i>Ther Drug Monit</i>. 1995;17(6):690-699.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/8588243/pubmed" id="8588243" target="_blank">8588243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17332971">
<a name="17332971"></a>Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. <i>Clin Rheumatol</i>. 2007;26(11):1871-1875. doi:10.1007/s10067-007-0596-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17332971/pubmed" id="17332971" target="_blank">17332971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16863458">
<a name="16863458"></a>Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. <i>Expert Opin Drug Metab Toxicol</i>. 2005;1(3):505-526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16863458/pubmed" id="16863458" target="_blank">16863458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26082342">
<a name="26082342"></a>Siddiqi N, Lamour JM, Hsu DT. The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. <i>Pediatr Transplant</i>. 2015;19(6):618-622. doi:10.1111/petr.12542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/26082342/pubmed" id="26082342" target="_blank">26082342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117026">
<a name="24117026"></a>Sieb JP. Myasthenia gravis: an update for the clinician. <i>Clin Exp Immunol</i>. 2014;175(3):408-418. doi:10.1111/cei.12217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/24117026/pubmed" id="24117026" target="_blank">24117026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17198262">
<a name="17198262"></a>Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy Outcomes in Solid Organ Transplant Recipients With Exposure to Mycophenolate Mofetil or Sirolimus. <i>Transplantation</i>. 2006;82(12):1698-1702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17198262/pubmed" id="17198262" target="_blank">17198262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21881859">
<a name="21881859"></a>Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laqué R, Vilardell-Tarrés M. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. <i>Clin Rheumatol.</i> 2011;30(11):1393-1398. doi:10.1007/s10067-011-1823-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21881859/pubmed" id="21881859" target="_blank">21881859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16436959">
<a name="16436959"></a>Smith JM, Rudser K, Gillen D, et al. Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. <i>Transplantation</i>. 2006;81(2):175-180. doi:10.1097/01.tp.0000188687.18972.a8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16436959/pubmed" id="16436959" target="_blank">16436959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23758434">
<a name="23758434"></a>Sobiak J, Kamińska J, Głyda M, Duda G, Chrzanowska M. Effect of mycophenolate mofetil on hematological side effects incidence in renal transplant recipients. <i>Clin Transplant</i>. 2013;27(4):E407-E414. doi:10.1111/ctr.12164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/23758434/pubmed" id="23758434" target="_blank">23758434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7645033">
<a name="7645033"></a>Sollinger HW. Mycophenolate Mofetil for the Prevention of Acute Rejection in Primary Cadaveric Renal Allograft Recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. <i>Transplantation</i>. 1995;60:225-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/7645033/pubmed" id="7645033" target="_blank">7645033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20177347">
<a name="20177347"></a>Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients. <i>Transplantation</i>. 2010;89(4):446-451. doi:10.1097/TP.0b013e3181ca860d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20177347/pubmed" id="20177347" target="_blank">20177347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31028595">
<a name="31028595"></a>Spasić A, Catić-Đorđević A, Veličković-Radovanović R, Stefanović N, Džodić P, Cvetković T. Adverse effects of mycophenolic acid in renal transplant recipients: gender differences. <i>Int J Clin Pharm</i>. 2019;41(3):776-784. doi:10.1007/s11096-019-00837-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/31028595/pubmed" id="31028595" target="_blank">31028595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20394831">
<a name="20394831"></a>Speich R, Schneider S, Hofer M, et al. Mycophenolate mofetil reduces alveolar inflammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation. <i>Pulm Pharmacol Ther</i>. 2010;23(5):445-449.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20394831/pubmed" id="20394831" target="_blank">20394831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17201457">
<a name="17201457"></a>Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. <i>Clin Pharmacokinet</i>. 2007;46(1):13-58. doi:10.2165/00003088-200746010-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17201457/pubmed" id="17201457" target="_blank">17201457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24792322">
<a name="24792322"></a>Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. <i>Arch Toxicol.</i> 2014;88(7):1351-1389. doi:10.1007/s00204-014-1247-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/24792322/pubmed" id="24792322" target="_blank">24792322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25836768">
<a name="25836768"></a>Subedi A, Magder LS, Petri M. Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. <i>Rheumatol Int</i>. 2015;35(10):1687-1692. doi:10.1007/s00296-015-3265-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/25836768/pubmed" id="25836768" target="_blank">25836768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21940156">
<a name="21940156"></a>Suwelack B, Malyar V, Koch M, Sester M, Sommerer C. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. <i>Transplant Rev (Orlando)</i>. 2012;26(3):201-211. doi:10.1016/j.trre.2011.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21940156/pubmed" id="21940156" target="_blank">21940156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26980727">
<a name="26980727"></a>Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i>. 2016;127(20):2375-2390. doi:10.1182/blood-2016-01-643569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/26980727/pubmed" id="26980727" target="_blank">26980727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16224194">
<a name="16224194"></a>Szyper-Kravitz M, Sheinberg P, Sidi Y, Schiffenbauer Y, Trubniykov E, Shoenfeld Y. Hypersensitivity to mycophenolate mofetil in systemic lupus erythematosus: diagnostic measures and successful desensitization. <i>Int Arch Allergy Immunol</i>. 2005;138(4):334-336. doi:10.1159/000088873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16224194/pubmed" id="16224194" target="_blank">16224194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28408734">
<a name="28408734"></a>Takahashi K, Go P, Stone CH, et al. Mycophenolate mofetil and pulmonary fibrosis after kidney transplantation: a case report. <i>Am J Case Rep</i>. 2017;18:399-404. doi:10.12659/ajcr.902380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28408734/pubmed" id="28408734" target="_blank">28408734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16014059">
<a name="16014059"></a>Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. <i>Kidney Int</i>. 2005;68(2):802-812. doi:10.1111/j.1523-1755.2005.00460.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16014059/pubmed" id="16014059" target="_blank">16014059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20032964">
<a name="20032964"></a>Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. <i>Kidney Int</i>. 2010;77(6):543-549. doi:10.1038/ki.2009.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20032964/pubmed" id="20032964" target="_blank">20032964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27469583">
<a name="27469583"></a>Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respir Med.</i> 2016;4:708-719. doi:10.1016/S2213-2600(16)30152-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/27469583/pubmed" id="27469583" target="_blank">27469583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenbaum.1">
<a name="Rosenbaum.1"></a>Thorne JE. Uveitis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21470310">
<a name="21470310"></a>Toledo AH, Hendrix L, Buchholz V, et al. Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients. <i>Clin Transplant</i>. 2012;26(1):156-163. doi:10.1111/j.1399-0012.2011.01444.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21470310/pubmed" id="21470310" target="_blank">21470310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11343977">
<a name="11343977"></a>Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. <i>J Heart Lung Transplant</i>. 2001;20(5):511-517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11343977/pubmed" id="11343977" target="_blank">11343977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8623181">
<a name="8623181"></a>Tricontinental Mycophenolate Mofetil Renal Transplantation (TMMRT) Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. <i>Transplantation</i>. 1996;61(7):1029-1037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/8623181/pubmed" id="8623181" target="_blank">8623181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19897521">
<a name="19897521"></a>Tsang HHL, Trendell-Smith NJ, Wu AKP, Mok MY. Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus. <i>Lupus</i>. 2010;19(3):330-3. doi:10.1177/0961203309347921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19897521/pubmed" id="19897521" target="_blank">19897521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27079159">
<a name="27079159"></a>Tull TJ, Toma T, Menagé HP. Reversible interstitial lung disease following treatment of atopic dermatitis with mycophenolate mofetil. <i>Clin Exp Dermatol</i>. 2016;41(6):702-703. doi:10.1111/ced.12843<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/27079159/pubmed" id="27079159" target="_blank">27079159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957821">
<a name="29957821"></a>Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. <i>Cochrane Database Syst Rev</i>. 2018;6(6):CD002922. doi:10.1002/14651858.CD002922.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/29957821/pubmed" id="29957821" target="_blank">29957821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19753679">
<a name="19753679"></a>Tutor-Crespo MJ, Hermida J, Romero R, Tutor JC. Two sampling time profiles for the abbreviated estimation of mycophenolic acid area under the curve in adult renal transplant recipients treated with mycophenolate mofetil and concomitant tacrolimus. <i>J Clin Pharm Ther</i>. 2009;34(5):531-537.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19753679/pubmed" id="19753679" target="_blank">19753679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11294511">
<a name="11294511"></a>van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. <i>Ther Drug Monit</i>. 2001;23(2):119-128. doi:10.1097/00007691-200104000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11294511/pubmed" id="11294511" target="_blank">11294511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16628123">
<a name="16628123"></a>van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. <i>Ther Drug Monit</i>. 2006;28(2):145-154. doi:10.1097/01.ftd.0000199358.80013.bd<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16628123/pubmed" id="16628123" target="_blank">16628123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16452491">
<a name="16452491"></a>van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. <i>J Am Soc Nephrol</i>. 2006;17(3):871-880. doi:10.1681/ASN.2005101070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/16452491/pubmed" id="16452491" target="_blank">16452491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28869324">
<a name="28869324"></a>Varnell CD, Fukuda T, Kirby CL, et al. Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs. <i>Pediatr Transplant</i>. 2017;21(7):10.1111/petr.13033. doi:10.1111/petr.13033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/28869324/pubmed" id="28869324" target="_blank">28869324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30728897">
<a name="30728897"></a>Velvet AJJ, Bhutani S, Papachristos S, et al. A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature. <i>Oncotarget</i>. 2019;10(4):437-448. doi:10.18632/oncotarget.26522<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/30728897/pubmed" id="30728897" target="_blank">30728897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vleugels.1">
<a name="Vleugels.1"></a>Vleugels RA. Management of refractory cutaneous dermatomyositis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11548843">
<a name="11548843"></a>Vogelsang GB, Arai S. Mycophenolate Mofetil for the Prevention and Treatment of Graft-Versus-Host Disease Following Stem Cell Transplantation: Preliminary Findings. <i> Bone Marrow Transplant</i>. 2001;27(12):1255-1262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11548843/pubmed" id="11548843" target="_blank">11548843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27502733">
<a name="27502733"></a>von Moos S, Cippà PE, Wüthrich RP, Mueller TF. Intestinal infection at onset of mycophenolic acid-associated chronic diarrhea in kidney transplant recipients. <i>Transpl Infect Dis</i>. 2016;18(5):721-729. doi:10.1111/tid.12590<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/27502733/pubmed" id="27502733" target="_blank">27502733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15518748">
<a name="15518748"></a>Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. <i>Transplant Proc</i>. 2004;36(7):2068-2070. doi:10.1016/j.transproceed.2004.07.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/15518748/pubmed" id="15518748" target="_blank">15518748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26525836">
<a name="26525836"></a>Wang Z, He JJ, Liu XY, et al. The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China. <i>Immunopharmacol Immunotoxicol</i>. 2015;37(6):508-512. doi: 10.3109/08923973.2015.1096286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/26525836/pubmed" id="26525836" target="_blank">26525836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29233098">
<a name="29233098"></a>Weber NT, Sigaroudi A, Ritter A, et al. Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report. <i>BMC Nephrol</i>. 2017;18(1):360. doi:10.1186/s12882-017-0757-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/29233098/pubmed" id="29233098" target="_blank">29233098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11349266">
<a name="11349266"></a>Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. <i>Liver Transpl</i>. 2001;7(5):442-450. doi:10.1053/jlts.2001.23356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/11349266/pubmed" id="11349266" target="_blank">11349266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20685255">
<a name="20685255"></a>Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-line treatment of chronic graft-versus-host disease. <i>Biol Blood Marrow Transplant</i>. 2011;17(1):1-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/20685255/pubmed" id="20685255" target="_blank">20685255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29114741">
<a name="29114741"></a>Wolstencroft PW, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Factors associated with clinical remission of skin disease in dermatomyositis. <i>JAMA Dermatol</i>. 2018;154(1):44-51. doi:10.1001/jamadermatol.2017.3758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/29114741/pubmed" id="29114741" target="_blank">29114741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626343">
<a name="19626343"></a>Wong SN, Chan WK, Hui J, et al. Membranous lupus nephritis in Chinese children--a case series and review of the literature. <i>Pediatr Nephrol</i>. 2009;24(10):1989-1996.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19626343/pubmed" id="19626343" target="_blank">19626343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24864029">
<a name="24864029"></a>Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series. <i>Int J Rheum Dis.</i> 2014;17(8):923-928. doi:10.1111/1756-185X.12399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/24864029/pubmed" id="24864029" target="_blank">24864029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26991238">
<a name="26991238"></a>Zachou K, Gatselis NK, Arvaniti P, et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. <i>Aliment Pharmacol Ther</i>. 2016;43(10):1035-1047.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/26991238/pubmed" id="26991238" target="_blank">26991238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21976398">
<a name="21976398"></a>Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. <i>Lupus</i>. 2011;20(14):1484-1493. doi:10.1177/0961203311418269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/21976398/pubmed" id="21976398" target="_blank">21976398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeiser.1">
<a name="Zeiser.1"></a>Zeiser R. Prevention of graft-versus-host disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17405792">
<a name="17405792"></a>Zhu B, Chen N, Lin Y, et al. Mycophenolate Mofetil in Induction and Maintenance Therapy of Severe Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials. <i>Nephrol Dial Transplant.</i> 2007;22(7):1933-1942.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/17405792/pubmed" id="17405792" target="_blank">17405792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12698153">
<a name="12698153"></a>Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. <i>J Thorac Cardiovasc Surg</i>. 2003;125(4):891-900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/12698153/pubmed" id="12698153" target="_blank">12698153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19345081">
<a name="19345081"></a>Zuk DM, Pearson GJ. Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients--a systematic review. <i>Transplant Rev (Orlando)</i>. 2009;23(3):171-177. doi:10.1016/j.trre.2009.02.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-mycophenolate-sodium-myfortic-drug-information/abstract-text/19345081/pubmed" id="19345081" target="_blank">19345081</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9670 Version 672.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
